JPWO2020089343A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020089343A5 JPWO2020089343A5 JP2021523658A JP2021523658A JPWO2020089343A5 JP WO2020089343 A5 JPWO2020089343 A5 JP WO2020089343A5 JP 2021523658 A JP2021523658 A JP 2021523658A JP 2021523658 A JP2021523658 A JP 2021523658A JP WO2020089343 A5 JPWO2020089343 A5 JP WO2020089343A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- stimulating
- stationary phase
- streptavidin
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 202
- 230000004936 stimulating Effects 0.000 claims description 153
- 230000005526 G1 to G0 transition Effects 0.000 claims description 100
- 239000003153 chemical reaction reagent Substances 0.000 claims description 86
- 108010090804 Streptavidin Proteins 0.000 claims description 76
- 230000027455 binding Effects 0.000 claims description 61
- 239000003795 chemical substances by application Substances 0.000 claims description 59
- 239000000126 substance Substances 0.000 claims description 54
- 239000003550 marker Substances 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 44
- 210000004027 cells Anatomy 0.000 claims description 39
- 239000002269 analeptic agent Substances 0.000 claims description 29
- 102000004965 antibodies Human genes 0.000 claims description 29
- 108090001123 antibodies Proteins 0.000 claims description 29
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 26
- 239000011230 binding agent Substances 0.000 claims description 21
- 230000000977 initiatory Effects 0.000 claims description 21
- 210000000662 T-Lymphocyte Subsets Anatomy 0.000 claims description 20
- 229960002685 biotin Drugs 0.000 claims description 20
- 108010018381 streptavidin-binding peptide Proteins 0.000 claims description 20
- 150000001615 biotins Chemical class 0.000 claims description 18
- 230000035693 Fab Effects 0.000 claims description 14
- 235000020958 biotin Nutrition 0.000 claims description 14
- 239000011616 biotin Substances 0.000 claims description 14
- 230000005484 gravity Effects 0.000 claims description 14
- 238000003306 harvesting Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 230000000638 stimulation Effects 0.000 claims description 13
- 102100019461 CD28 Human genes 0.000 claims description 12
- 101700033362 CD28 Proteins 0.000 claims description 12
- 102000000584 Calmodulin Human genes 0.000 claims description 12
- 108010041952 Calmodulin Proteins 0.000 claims description 12
- 150000001413 amino acids Chemical group 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- 239000002609 media Substances 0.000 claims description 11
- 108090001008 Avidin Proteins 0.000 claims description 10
- 102100008151 CCR7 Human genes 0.000 claims description 10
- 108010020195 FLAG peptide Proteins 0.000 claims description 10
- 101700036258 MECOM Proteins 0.000 claims description 10
- XZWYTXMRWQJBGX-VXBMVYAYSA-N (2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-carbox Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 claims description 9
- 101700056583 CD27 Proteins 0.000 claims description 9
- 102100019459 CD27 Human genes 0.000 claims description 9
- 230000003612 virological Effects 0.000 claims description 9
- 102000007312 Recombinant Proteins Human genes 0.000 claims description 8
- 108010033725 Recombinant Proteins Proteins 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 235000000638 D-biotin Nutrition 0.000 claims description 6
- 239000011665 D-biotin Substances 0.000 claims description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 5
- 108090000172 Interleukin-15 Proteins 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 238000002617 apheresis Methods 0.000 claims description 5
- 239000012504 chromatography matrix Substances 0.000 claims description 5
- 230000000875 corresponding Effects 0.000 claims description 5
- 230000002708 enhancing Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 229920002395 Aptamer Polymers 0.000 claims description 4
- 102100003729 CD40LG Human genes 0.000 claims description 4
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 4
- 108010012236 Chemokines Proteins 0.000 claims description 4
- 101700079540 FAS Proteins 0.000 claims description 4
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 101700026084 THY1 Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000038129 antigens Human genes 0.000 claims description 4
- 108091007172 antigens Proteins 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 108091022076 maltose binding proteins Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 230000003100 immobilizing Effects 0.000 claims description 3
- 210000004369 Blood Anatomy 0.000 claims description 2
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims description 2
- 108010078791 Carrier Proteins Proteins 0.000 claims description 2
- 229940022766 EGTA Drugs 0.000 claims description 2
- 102100016439 FAS Human genes 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 101700026790 LAT Proteins 0.000 claims description 2
- 101700005306 LYC1 Proteins 0.000 claims description 2
- 210000000265 Leukocytes Anatomy 0.000 claims description 2
- 210000004698 Lymphocytes Anatomy 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 102100004033 SPNS1 Human genes 0.000 claims description 2
- 101700027603 SPNS1 Proteins 0.000 claims description 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 102100008333 THY1 Human genes 0.000 claims description 2
- 102100008790 TNFRSF14 Human genes 0.000 claims description 2
- 101710040448 TNFRSF4 Proteins 0.000 claims description 2
- 102100013135 TNFRSF4 Human genes 0.000 claims description 2
- 230000003213 activating Effects 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 238000005138 cryopreservation Methods 0.000 claims description 2
- 230000001082 cryoprotectant Effects 0.000 claims description 2
- 239000002577 cryoprotective agent Substances 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 2
- 230000001404 mediated Effects 0.000 claims description 2
- 210000003071 memory T lymphocyte Anatomy 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 230000002062 proliferating Effects 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 230000001177 retroviral Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 229910001428 transition metal ion Inorganic materials 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims 5
- 102000005720 Glutathione Transferase family Human genes 0.000 claims 1
- 108010070675 Glutathione Transferase family Proteins 0.000 claims 1
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 claims 1
- MYVYPSWUSKCCHG-JQWIXIFHSA-N Trp-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 MYVYPSWUSKCCHG-JQWIXIFHSA-N 0.000 claims 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 description 5
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 229960002743 Glutamine Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000002443 helper T lymphocyte Anatomy 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 230000003522 irritant Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003068 static Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
Description
自動で実行されてもよい本明細書において提供される方法（その態様を含む）のいずれかにおいて使用するための装置および/または製造物品が提供される。
[本発明1001]
以下の工程を含む、T細胞のオンカラム刺激方法:
T細胞において刺激シグナルを送達する能力を有するオリゴマー刺激試薬を、複数の固定化T細胞を含む固定相に加え、それによって、該刺激試薬と1つまたは複数のT細胞とのインキュベーションを開始する工程であって、
該固定相が、1つまたは複数のT細胞またはそのサブセットの表面上の選択マーカーに特異的に結合する選択物質を含み、
該オリゴマー刺激試薬が、（i）抗CD3抗体である第1刺激物質と（ii）抗CD28抗体である第2刺激物質とを含む1つまたは複数の刺激物質を含む、
工程;および
インキュベーション開始から24時間以内に、該複数のT細胞のうちの1つまたは複数を重力流によって該固定相から収集し、それによって、刺激されたT細胞を含む組成物を生成する工程。
[本発明1002]
以下の工程を含む、T細胞のオンカラム刺激方法:
（a）固定相上に固定化された複数のT細胞を1つまたは複数の刺激物質と共にインキュベートして、該複数のT細胞のうちの1つまたは複数のT細胞において刺激シグナルを送達する工程であって、該固定相が、該1つまたは複数のT細胞の表面上の選択マーカーに特異的に結合する選択物質を含み、該1つまたは複数のT細胞によって発現された該選択マーカーへの該選択物質の特異的結合が、該1つまたは複数のT細胞を該固定相上に固定化する、工程;および
（b）インキュベーションの開始から24時間以内に、該1つまたは複数のT細胞を重力流によって該固定相から収集し、それによって、刺激されたT細胞を含む組成物を生成する工程。
[本発明1003]
固定相が、1つまたは複数のT細胞において刺激シグナルを送達する能力を有する1つまたは複数の刺激物質のうちの少なくとも1つを含むか、あるいは該1つまたは複数の刺激物質のうちの少なくとも1つと共に固定化される、本発明1002の方法。
[本発明1004]
1つまたは複数の刺激物質が第1刺激物質および第2刺激物質であり、インキュベートすることに先立って、第1刺激物質の刺激シグナルを増強、減弱または改変する能力を有する第2刺激物質を含む刺激試薬が固定相に加えられる、本発明1002の方法。
[本発明1005]
インキュベートすることに先立って、1つまたは複数の刺激物質のうちの少なくとも1つを含む刺激試薬を固定相に加える工程を含む、本発明1002の方法。
[本発明1006]
少なくとも1つの刺激物質が第1刺激物質であり、1つまたは複数の刺激物質が、第1刺激物質の刺激シグナルを増強、減弱または改変する能力を有する第2刺激物質をさらに含む、本発明1005の方法。
[本発明1007]
1つまたは複数の刺激物質のうちの少なくとも1つ、任意で第1刺激物質が、刺激シグナルを送達する能力を有し、該刺激シグナルが、T細胞中のTCR/CD3複合体、T細胞中のCD3含有複合体および/またはT細胞中のITAM含有分子を介した刺激シグナルである、本発明1002～1006のいずれかの方法。
[本発明1008]
第2刺激物質が、1つまたは複数のT細胞上の共刺激分子に特異的に結合する能力を有する、本発明1004、1006および1007のいずれかの方法。
[本発明1009]
以下の工程を含む、T細胞のオンカラム刺激方法:
（a）複数のT細胞を含む試料を固定相に加える工程であって、該固定相が、該複数のT細胞のうちの1つまたは複数の表面上の選択マーカーに結合する選択物質を含み、それによって、複数のT細胞のうちの該1つまたは複数が該固定相上に固定化される、工程;
（b）該複数のT細胞のうちの1つまたは複数において刺激シグナルを送達する能力を有する1つまたは複数の刺激物質を含む刺激試薬を該固定相に加え、それによって、該刺激試薬と該1つまたは複数のT細胞とのインキュベーションを開始する工程;および
（c）インキュベーション開始から24時間以内に、該複数のT細胞のうちの1つまたは複数を重力流によって該固定相から収集し、それによって、刺激されたT細胞を含む組成物を生成する工程。
[本発明1010]
以下の工程を含む、T細胞のオンカラム刺激方法:
（1）（a）複数のT細胞を含む試料と（b）該複数のT細胞のうちの1つまたは複数の表面に発現した選択マーカーに特異的に結合する能力を有する選択物質を含む固定相とを混合する工程であって、選択マーカーに対する該選択物質の特異的結合が、該複数のT細胞のうちの該1つまたは複数を該固定相に固定化する、工程;
（2）T細胞において刺激シグナルを送達する能力を有する1つまたは複数の刺激物質を含む刺激試薬を該固定相に加え、それによって、該刺激試薬と該1つまたは複数のT細胞とのインキュベーションを開始する工程;および
（3）インキュベーション開始から24時間以内に、該複数のT細胞のうちの1つまたは複数を重力流によって該固定相から収集し、それによって、刺激されたT細胞を含む組成物を生成する工程。
[本発明1011]
以下の工程を含む、T細胞のオンカラム刺激方法:
オリゴマー刺激試薬を、複数の固定化T細胞を含む固定相に加え、それによって、該刺激試薬と該複数の固定化T細胞のうちの1つまたは複数のT細胞とのインキュベーションを開始する工程であって、
該固定相が、1つまたは複数のT細胞の表面上の選択マーカーに特異的に結合する選択物質を含み、該1つまたは複数のT細胞によって発現された該選択マーカーへの該選択物質の特異的結合が、該1つまたは複数のT細胞を該固定相に固定化し、
該オリゴマー刺激試薬が、（i）複数のストレプトアビジン分子またはストレプトアビジンムテイン分子と（ii）1つまたは複数のT細胞において刺激シグナルを送達する能力を有する1つまたは複数の刺激物質とを含み、該オリゴマー刺激試薬のサイズが、（i）50nm超の半径、（ii）少なくとも5×10
6
g/molの分子量および/または（iii）オリゴマー刺激試薬あたり少なくとも100個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体を含む、
工程。
[本発明1012]
インキュベーション開始から24時間以内に、複数のT細胞のうちの1つまたは複数を重力流によって固定相から収集し、それによって、刺激されたT細胞を含む組成物を生成する工程をさらに含む、本発明1011の方法。
[本発明1013]
複数のT細胞のうちの1つまたは複数を固定相から収集することが、インキュベーション開始から約23、22、21、20、19、18、17、16、15、14、13、12、11、10、9、8、7、6、5、4、3または2時間以内に行われる、本発明1001～1010または1012のいずれかの方法。
[本発明1014]
複数のT細胞のうちの1つまたは複数を固定相から収集することが、インキュベーション開始から約2～24、3～24、4～24、5～24、6～24、7～24、8～24、9～24、10～24、11～24、12～24、13～24、14～24、15～24、16～24、17～24、18～24、19～24、20～24、21～24、22～24、23～24、2～23、2～22、2～21、2～20、2～19、2～18、2～17、2～16、2～15、2～14、2～13、2～12、2～11、2～10、2～9、2～8、2～7、2～6、2～5、2～4または2～3時間以内に行われる、本発明1001～1010、1012または1013のいずれかの方法。
[本発明1015]
複数のT細胞のうちの1つまたは複数を固定相から収集することが、インキュベーション開始から約12、10、8、6、4または2時間以内に行われる、本発明1001～1010または1012～1014のいずれかの方法。
[本発明1016]
複数のT細胞のうちの1つまたは複数を固定相から収集することが、インキュベーション開始から5時間以内に行われる、本発明1001～1010または1012～1015のいずれかの方法。
[本発明1017]
複数のT細胞のうちの1つまたは複数を固定相から収集することが、インキュベーション開始から4.5時間以内または約4.5時間以内に行われる、本発明1001～1010または1012～1016のいずれかの方法。
[本発明1018]
複数のT細胞のうちの1つまたは複数を固定相から収集することが、インキュベーション開始から4時間以内に行われる、本発明1001～1010または1012～1017のいずれかの方法。
[本発明1019]
刺激試薬とのインキュベーションの開始が、複数のT細胞を含む試料を固定相に加えた後または固定相と混合した後、10分以内もしくは約10分以内、20分以内もしくは約20分以内、30分以内もしくは約30分以内、45分以内もしくは約45分以内、60分以内もしくは約60分以内、90分以内もしくは約90分以内または120分以内もしくは約120分以内に実行される、本発明1001、1009、1010および1013～1017のいずれかの方法。
[本発明1020]
刺激試薬とのインキュベーションの開始が、複数のT細胞を含む試料を固定相に加えた後または固定相と混合した後、60分以内または約60分以内に実行される、本発明1001、1009、1010および1013～1019のいずれかの方法。
[本発明1021]
1つまたは複数の刺激物質のうちの少なくとも1つが、刺激シグナルを送達する能力を有し、該刺激シグナルが、T細胞中のTCR/CD3複合体、T細胞中のCD3含有複合体および/またはT細胞中のITAM含有分子を介した刺激シグナルである、本発明1009～1020のいずれかの方法。
[本発明1022]
少なくとも1つの刺激物質が第1刺激物質であり、刺激試薬が、第1刺激物質の刺激シグナルを増強、減弱または改変する能力を有する第2刺激物質のうちの1つまたは複数をさらに含む、本発明1021の方法。
[本発明1023]
第2刺激物質が、1つまたは複数のT細胞上の共刺激分子に特異的に結合する能力を有する、本発明1004、1006、1007および1022のいずれかの方法。
[本発明1024]
共刺激分子がCD28、CD90（Thy-1）、CD95（Apo-/Fas）、CD137（4-1BB）、CD154（CD40L）、ICOS、LAT、CD27、OX40またはHVEMの中から選択される、本発明1008または本発明1023の方法。
[本発明1025]
第2刺激物質がCD28に特異的に結合する能力を有し、および/または共刺激分子がCD28である、本発明1008、本発明1023または本発明1024の方法。
[本発明1026]
第1刺激物質がCD3に特異的に結合し、第2刺激物質がCD28に特異的に結合する、本発明1014、1006、1007、1008および1020～1023のいずれかの方法。
[本発明1027]
1つまたは複数の刺激物質が、独立して、抗体フラグメント、一価抗体フラグメント、免疫グロブリン様機能を持つタンパク質性結合分子、Igドメインを含有する分子、サイトカイン、ケモカイン、アプタマー、MHC分子、MHC-ペプチド複合体;受容体リガンド;およびその結合性フラグメントからなる群より選択される物質であるか、またはそれを含む、
本発明1001～1026のいずれかの方法。
[本発明1028]
第1刺激物質および第2刺激物質が、独立して、抗体フラグメント、一価抗体フラグメント、免疫グロブリン様機能を持つタンパク質性結合分子、Igドメインを含有する分子、サイトカイン、ケモカイン、アプタマー、MHC分子、MHC-ペプチド複合体;受容体リガンド;およびその結合性フラグメントからなる群より選択される物質であるか、またはそれを含む、
本発明1004、1006、1007、1008または1013～1020、1022～1264のいずれかの方法。
[本発明1029]
1つまたは複数の刺激物質が一価抗体フラグメントを含む、本発明1001～1027のいずれかの方法。
[本発明1030]
第1刺激物質および第2刺激物質が、独立して、一価抗体フラグメントを含む、本発明1001、1004、1006、1007、1008、1013～1020、1022～1026および1028のいずれかの方法。
[本発明1031]
第1刺激物質が、CD3に結合する一価抗体フラグメントを含み、第2刺激物質が、CD28に結合する一価抗体フラグメントを含む、本発明1001、1004、1006、1007、1008、1013～1020、1022～1026、1028および1030のいずれかの方法。
[本発明1032]
一価抗体フラグメントが、Fabフラグメント、Fvフラグメントおよび一本鎖Fvフラグメント（scFv）からなる群より選択される、本発明1027～1031のいずれかの方法。
[本発明1033]
第1刺激物質が抗CD3 Fabであり、第2刺激物質が抗CD28 Fabである、本発明1001、1004、1006、1007、1008、1013～1020、1022～1026、1028および1030～1032のいずれかの方法。
[本発明1034]
以下の工程を含む、T細胞のオンカラム刺激方法:
T細胞において刺激シグナルを送達する能力を有するオリゴマー刺激試薬を、複数の固定化T細胞を含む固定相に加え、それによって、該刺激試薬と1つまたは複数のT細胞とのインキュベーションを開始する工程であって、
該固定相が、1つまたは複数のT細胞またはそのサブセットの表面上の選択マーカーに特異的に結合する能力を有する選択物質を含み、該1つまたは複数のT細胞またはそのサブセットによって発現された選択マーカーに対する該選択物質の特異的結合が、該少なくとも複数のT細胞を該固定相に固定化し、該選択物質が、CD3、CD4およびCD8からなる群より選択される選択マーカーに特異的に結合する能力を有するFabフラグメントであり;
該オリゴマー刺激試薬が、（i）複数のストレプトアビジンムテイン分子、（ii）CD3に特異的に結合する能力を有するFabフラグメントであり、1つまたは複数のT細胞において刺激シグナルを送達する能力を有する第1刺激物質、および（iii）CD28に特異的に結合する能力を有するFabフラグメントであり、刺激シグナルを増強、減弱または改変する能力を有する第2刺激物質を含み、該オリゴマー刺激試薬のサイズが、（i）50nm超の半径、（ii）少なくとも5×10
6
g/molの分子量、および/または（iii）オリゴマー刺激試薬あたり少なくとも100個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体を含む、
工程;ならびに
インキュベーション開始から24時間以内に、該複数のT細胞のうちの1つまたは複数を重力流によって該固定相から収集し、それによって、刺激されたT細胞を含む組成物を生成する工程。
[本発明1035]
T細胞が、全血試料、バフィーコート試料、末梢血単核球（PBMC）試料、未分画T細胞試料、リンパ球試料、白血球試料、アフェレーシス産物または白血球アフェレーシス産物であるかそれを含む試料に由来する、本発明1001～1034のいずれかの方法。
[本発明1036]
試料がアフェレーシス産物または白血球アフェレーシス産物である、本発明1035のいずれかの方法。
[本発明1037]
アフェレーシス産物または白血球アフェレーシス産物が以前にクライオ凍結（cryofrozen）されている、本発明1036のいずれかの方法。
[本発明1038]
1つまたは複数の刺激物質と共にインキュベートすることが、複数の固定化T細胞のうちの1つまたは複数を固定相から遊離させる、本発明1002～1027および1029のいずれかの方法。
[本発明1039]
第1刺激物質および第2刺激物質と共にインキュベートすることが、複数の固定化T細胞のうちの1つまたは複数を固定相から遊離させる、本発明1001、1004、1006、1007、1008、1013～1020、1022～1026、1028、1030～1038のいずれかの方法。
[本発明1040]
1つまたは複数の刺激物質が、ビオチン、ストレプトアビジンまたはアビジンに可逆的に結合するビオチン類似体、
[本発明1041]
1つまたは複数の刺激物質が、
[本発明1042]
1つまたは複数の刺激物質が、配列
[本発明1043]
第1刺激物質および第2刺激物質が、独立して、ビオチン、ストレプトアビジンまたはアビジンに可逆的に結合するビオチン類似体、
[本発明1044]
第1刺激物質および第2刺激物質のそれぞれが、
[本発明1045]
第1刺激物質および第2刺激物質のそれぞれが、配列
[本発明1046]
選択物質が、抗体フラグメント、一価抗体フラグメント、免疫グロブリン様機能を持つタンパク質性結合分子、Igドメインを含有する分子、サイトカイン、ケモカイン、アプタマー、MHC分子、MHC-ペプチド複合体;受容体リガンド;およびその結合性フラグメントからなる群より選択される物質であるか、またはそれを含む、本発明1001～1045のいずれかの方法。
[本発明1047]
選択マーカーがT細胞補助受容体であり;
選択マーカーがT細胞抗原受容体複合体のメンバーであるか、もしくはそれを含み、
選択マーカーがCD3鎖であるか、もしくはそれを含み、
選択マーカーがCD3ゼータ鎖であるか、もしくはそれを含み、
選択マーカーがCD8であるか、もしくはそれを含み;
選択マーカーがCD4であるか、もしくはそれを含み、
選択マーカーがCD45RAであるか、もしくはそれを含み;
選択マーカーがCD27であるか、もしくはそれを含み、
選択マーカーがCD28であるか、もしくはそれを含み、および/または
選択マーカーがCCR7であるか、もしくはそれを含む、
本発明1001～1046のいずれかの方法。
[本発明1048]
選択マーカーが、CD3、CD4およびCD8からなる群より選択される、本発明1001～1047のいずれかの方法。
[本発明1049]
選択マーカーがCD3である、本発明1001～1048のいずれかの方法。
[本発明1050]
選択物質が、ビオチン、ストレプトアビジンまたはアビジンに可逆的に結合するビオチン類似体、
[本発明1051]
選択物質が、ビオチン、ストレプトアビジンまたはアビジンに可逆的に結合するビオチン類似体、
[本発明1052]
選択物質が、配列
[本発明1053]
選択物質と選択マーカーの間の特異的結合が、T細胞へのシグナルを誘導しないか、または、T細胞への刺激シグナル、活性化シグナルおよび増殖シグナルをいずれも誘導しない、本発明1001～1052のいずれかの方法。
[本発明1054]
選択物質が、CD3、CD8またはCD4に結合する一価抗体フラグメントを含む、本発明1001～1053のいずれかの方法。
[本発明1055]
選択物質が抗CD3 Fab、抗CD8 Fabまたは抗CD4 Fabである、本発明1001～1054のいずれかの方法。
[本発明1056]
選択物質が抗CD3 Fabである、本発明1001～1055のいずれかの方法。
[本発明1057]
刺激試薬が、複数のストレプトアビジン分子またはストレプトアビジンムテイン分子を含むオリゴマー刺激試薬であり、該オリゴマー粒子試薬のサイズが、（i）50nm超の半径、（ii）少なくとも5×10
6
g/molの分子量および/または（iii）オリゴマー刺激試薬あたり少なくとも100個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体を含む、本発明1004～1010、1013～1033および1035～1056のいずれかの方法。
[本発明1058]
オリゴマー刺激試薬が、複数のストレプトアビジン分子またはストレプトアビジンムテイン分子を含み、該オリゴマー粒子試薬のサイズが、（i）50nm超の半径、（ii）少なくとも5×10
6
g/molの分子量および/または（iii）オリゴマー刺激試薬あたり少なくとも100個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体を含む、本発明1001の方法。
[本発明1059]
オリゴマー刺激試薬が可溶性である、本発明1001、1011～1058のいずれかの方法。
[本発明1060]
オリゴマー刺激試薬が、固形支持体、固定相、ビーズ、微粒子、磁気粒子および/もしくはマトリックスではなく、かつそれらに結合も会合もしておらず、ならびに/または
該試薬が、フレキシブルであり、金属コアも磁気コアも含有せず、完全にもしくは主として有機多量体で構成され、かつ/もしくは剛直ではない、
本発明1001、1011～1059のいずれかの方法。
[本発明1061]
ストレプトアビジン分子またはストレプトアビジンムテイン分子が、ビオチン、ビオチン類似体もしくはストレプトアビジン結合ペプチドに可逆的に結合するか、または可逆的に結合する能力を有する、本発明1011～1060のいずれかの方法。
[本発明1062]
ストレプトアビジンムテインが、SEQ ID NO:1に示すアミノ酸の配列におけるストレプトアビジン中の位置を基準として位置44～47に対応する配列位置に、アミノ酸配列Ile
44
-Gly
45
-Ala
46
-Arg
47
を含むか、または
ストレプトアビジンムテインが、SEQ ID NO:1に示すアミノ酸の配列におけるストレプトアビジン中の位置を基準として位置44～47に対応する配列位置に、アミノ酸配列Val
44
-Thr
45
-Ala
46
-Arg
47
を含む、
本発明1011～1061のいずれかの方法。
[本発明1063]
ストレプトアビジン結合ペプチドが、
[本発明1064]
オリゴマー刺激試薬が、
60nm超、70nm超、80nm超または90nm超の半径
を含む、本発明1001および1011～1063のいずれかの方法。
[本発明1065]
オリゴマー刺激試薬が、
両端の値を含む50nm～150nm、75nm～125nm、80nm～115nmもしくは90nm～110nmの半径、または
90nm±15nmもしくは95nm±20～25nmの半径
を含む、本発明1001および1011～1064のいずれかの方法。
[本発明1066]
前記半径が流体力学的半径である、本発明1164のいずれかの方法。
[本発明1067]
オリゴマー刺激試薬が、
少なくとも5×10
7
g/molもしくは少なくとも1×10
8
g/mol、および/または
5×10
7
g/mol～5×10
8
g/mol、1×10
8
g/mol～5×10
8
g/mol、もしくは1×10
8
g/mol～2×10
8
g/mol
の分子量を含む、本発明1001および1011～1066のいずれかの方法。
[本発明1068]
オリゴマー刺激試薬が、
少なくとも500個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体、少なくとも1,000個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体、少なくとも1,500個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体、または少なくとも2,000個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体、および/または
1,000～20,000個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体、1,000～10,000個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体、または2,000～5,000個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体
を含む、本発明1001および1011～1067のいずれかの方法。
[本発明1069]
オリゴマー刺激試薬が、約1～約2μg/細胞100万個の濃度で固定相に加えられる、本発明1001および1011～1068のいずれかの方法。
[本発明1070]
選択物質が固定相に直接的または間接的に結合される、本発明1001～1069のいずれかの方法。
[本発明1071]
選択物質が、該選択物質が可逆的に結合する選択試薬を介して間接的に固定相に結合される、本発明1001～1070のいずれかの方法。
[本発明1072]
選択試薬が、ストレプトアビジン;アビジン;ビオチン、ビオチン類似体もしくは生物学的に活性なそのフラグメントに可逆的に結合するストレプトアビジンのムテイン;ストレプトアビジン結合ペプチドに可逆的に結合する、アビジンもしくはストレプトアビジンのムテイン;少なくとも2つのキレート基Kを含む試薬であって、該少なくとも2つのキレート基が、遷移金属イオンに結合する能力を有する、試薬;オリゴヒスチジンアフィニティータグに結合する能力を有する物質;グルタチオン-S-トランスフェラーゼに結合する能力を有する物質;カルモジュリンまたはその類似体;カルモジュリン結合ペプチド（CBP）に結合する能力を有する物質;FLAGペプチドに結合する能力を有する物質;HAタグに結合する能力を有する物質;マルトース結合タンパク質（MBP）に結合する能力を有する物質;HSVエピトープに結合する能力を有する物質;mycエピトープに結合する能力を有する物質;またはビオチン化担体タンパク質に結合する能力を有する物質であるか、またはそれを含む、本発明1070または本発明1071の方法。
[本発明1073]
選択試薬が、ビオチンもしくは生物学的に活性なフラグメントに可逆的に結合するストレプトアビジンムテインもしくはアビジンムテインであるか、またはそれを含み、
刺激試薬が、ビオチン類似体もしくは生物学的に活性なフラグメントに可逆的に結合するストレプトアビジンムテインもしくはアビジンムテインであるか、またはそれを含み、および/あるいは
刺激試薬が、ストレプトアビジン結合ペプチドに可逆的に結合するストレプトアビジンムテインもしくはアビジンムテインであるか、またはそれを含む、
本発明1070～1072のいずれかの方法。
[本発明1074]
ストレプトアビジン分子またはストレプトアビジンムテイン分子が、ビオチン、ビオチン類似体もしくはストレプトアビジン結合ペプチドに可逆的に結合するか、または可逆的に結合する能力を有する、本発明1072または本発明1073の方法。
[本発明1075]
ストレプトアビジンムテインが、SEQ ID NO:1に示すアミノ酸の配列におけるストレプトアビジン中の位置を基準として位置44～47に対応する配列位置に、アミノ酸配列Ile
44
-Gly
45
-Ala
46
-Arg
47
を含むか、または
ストレプトアビジンムテインが、SEQ ID NO:1に示すアミノ酸の配列におけるストレプトアビジン中の位置を基準として位置44～47に対応する配列位置に、アミノ酸配列Val
44
-Thr
45
-Ala
46
-Arg
47
を含む、
本発明1072～1074のいずれかの方法。
[本発明1076]
ストレプトアビジン結合ペプチドが、
[本発明1077]
ストレプトアビジン結合ペプチドが、配列
[本発明1078]
重力流によって収集することが、固定相からT細胞を溶出させるための競合剤も遊離結合剤（free binding agent）も含まない培地を固定相に加えることを含む、本発明1001～1010または1012～1077のいずれかの方法。
[本発明1079]
刺激されたT細胞を含む組成物が競合剤も遊離結合剤も含まない、本発明1001～1010および1012～1078のいずれかの方法。
[本発明1080]
競合剤または遊離結合剤が、ビオチンもしくはビオチン類似体であるか、またはそれを含み、任意で、該ビオチン類似体が、D-ビオチンである、本発明1078または1079の方法。
[本発明1081]
前記組成物の刺激されたT細胞に、組換えタンパク質をコードする組換え核酸分子を導入し、それによって、操作されたT細胞を含む組成物、任意で形質導入T細胞を含む組成物を作製する工程をさらに含む、本発明1001～1078のいずれかの方法。
[本発明1082]
組換えタンパク質が抗原受容体である、本発明1081の方法。
[本発明1083]
組換えタンパク質がキメラ抗原受容体である、本発明1081または本発明1082の方法。
[本発明1084]
キメラ抗原受容体（CAR）が、標的抗原に特異的に結合する細胞外抗原認識ドメインと、ITAMを含む細胞内シグナル伝達ドメインとを含む、本発明1083の方法。
[本発明1085]
細胞内シグナル伝達ドメインが、CD3ゼータ（CD3ζ）鎖の細胞内ドメインを含む、本発明1084の方法。
[本発明1086]
細胞外ドメインと細胞内シグナル伝達ドメインとを連結する膜貫通ドメインをさらに含む、本発明1084または本発明1085の方法。
[本発明1087]
膜貫通ドメインがCD28の膜貫通部分を含む、本発明1086の方法。
[本発明1088]
細胞内シグナル伝達ドメインがT細胞共刺激分子の細胞内シグナル伝達ドメインをさらに含む、本発明1084～1087のいずれかの方法。
[本発明1089]
T細胞共刺激分子が、CD28および41BBからなる群より選択される、本発明1088の方法。
[本発明1090]
前記核酸が、組換え抗原受容体をコードする核酸に機能的に連結されたプロモータをさらに含む、本発明1081～1089のいずれかの方法。
[本発明1091]
組換え核酸の導入が、ウイルス粒子を使った形質導入によって達成される、本発明1081～1090のいずれかの方法。
[本発明1092]
ウイルス粒子がレトロウイルスベクター粒子である、本発明1091の方法。
[本発明1093]
ウイルス粒子がレンチウイルスベクター粒子である、本発明1091または本発明1092の方法。
[本発明1094]
形質導入細胞を含む組成物を、ウイルス組込みのための条件下、任意で37°±2℃または約37°±2℃の温度で、インキュベートする工程をさらに含む、本発明1081～1093のいずれかの方法。
[本発明1095]
形質導入細胞を含む組成物をインキュベートする工程が、導入後、最大96時間にわたって実行される、本発明1094の方法。
[本発明1096]
形質導入細胞を含む組成物をインキュベートする工程が、導入後、最大72時間にわたって実行される、本発明1094の方法。
[本発明1097]
形質導入細胞を含む組成物をインキュベートする工程が、導入後、最大48時間にわたって実行される、本発明1094の方法。
[本発明1098]
形質導入細胞を含む組成物をインキュベートする工程が、導入後、最大24時間にわたって実行される、本発明1094の方法。
[本発明1099]
形質導入細胞を含む組成物をインキュベートする工程が、導入後、少なくとも18時間にわたって実行される、本発明1094～1098のいずれかの方法。
[本発明1100]
操作された細胞を含む組成物、任意で形質導入細胞を含む組成物を、T細胞を拡大培養するための条件下で培養する工程をさらに含む、本発明1081～1099のいずれかの方法。
[本発明1101]
培養する工程が14日以下、12日以下、10日以下、8日以下、6日以下または5日以下の時間にわたって実行される、本発明1100の方法。
[本発明1102]
操作されたT細胞を採取し、それによって、操作されたT細胞のアウトプット集団を作製する工程をさらに含む、本発明1081～1101のいずれかの方法。
[本発明1103]
刺激試薬への曝露を開始した後、両端の値を含む48～120時間の時点で、操作されたT細胞を採取する工程をさらに含む、本発明1081～1099のいずれかの方法。
[本発明1104]
刺激物質への曝露を開始した後、120時間以内に採取が実行される、本発明1081～1099および1103のいずれかの方法。
[本発明1105]
刺激物質への曝露を開始した後、96時間以内に採取が実行される、本発明1081～1099および1103のいずれかの方法。
[本発明1106]
刺激物質への曝露を開始した後、72時間以内に採取が実行される、本発明1081～1099および1105のいずれかの方法。
[本発明1107]
刺激物質への曝露を開始した後、48時間以内に採取が実行される、本発明1081～1099および1106のいずれかの方法。
[本発明1108]
ナイーブ様細胞のパーセンテージが、採取の時点で、集団中の全T細胞、集団中の全CD4＋T細胞、または集団中の全CD8＋T細胞もしくはその組換えタンパク質発現細胞のうちの60％超または約60％超である、本発明1102～1107のいずれかの方法。
[本発明1109]
ナイーブ様T細胞がCD27＋CCR7＋細胞を含む、本発明1108の方法。
[本発明1110]
導入が無血清培地中で実行される、本発明1081～1093のいずれかの方法。
[本発明1111]
インキュベートする工程が無血清培地中で実行される、本発明1094～1099のいずれかの方法。
[本発明1112]
培養する工程が無血清培地中で実行される、本発明1100または本発明1101の方法。
[本発明1113]
無血清培地が、
基本培地中、0.5mM～5mMのジペプチド型L-グルタミン、
0.5mM～5mM L-グルタミン、および
任意で少なくとも1つのタンパク質
を含み、該培地が血清を含まない、本発明1110～1112のいずれかの方法。
[本発明1114]
無血清培地が、IL-2、IL-15およびIL-7の中から選択される組換えサイトカイン、任意で、組換えヒトIL-2、組換えヒトIL-15および/または組換えヒトIL-7を含む、本発明1110～1113のいずれかの方法。
[本発明1115]
無血清培地が、IL-2、IL-15およびIL-7の中から選択される組換えサイトカイン、任意で、組換えヒトIL-2、組換えヒトIL-15および/または組換えヒトIL-7を含まない、本発明1110～1114のいずれかの方法。
[本発明1116]
操作された細胞を含む組成物、任意で形質導入T細胞を含む組成物に競合剤または遊離結合剤を加える工程をさらに含み、任意で、該剤が、1つまたは複数の刺激物質を該組成物中のオリゴマー刺激試薬から解離させるための条件下で加えられる、本発明1081～1093のいずれかの方法。
[本発明1117]
インキュベートされたT細胞を含む組成物に、任意で、1つまたは複数の刺激物質を該組成物中のオリゴマー刺激試薬から解離させるための条件下で、競合剤または遊離結合剤を加える工程をさらに含む、本発明1094～1099のいずれかの方法。
[本発明1118]
培養されたT細胞を含む組成物に、任意で、1つまたは複数の刺激物質を該組成物中のオリゴマー刺激試薬から解離させるための条件下で、競合剤または遊離結合剤を加える工程をさらに含む、本発明1100～1101のいずれかの方法。
[本発明1119]
競合剤または遊離結合剤を添加する工程が、採取に先立って実行される、本発明1116～1118のいずれかの方法。
[本発明1120]
競合剤もしくは遊離結合剤が、T細胞にとって有害ではなく、および/または、該物質の添加が、該競合剤も該遊離結合剤も使用しない同等もしくは同じ条件下でのT細胞のインキュベーションとの比較で、生残するT細胞のパーセンテージを90％未満、80％未満、70％未満、60％未満もしくは50％未満に低減させることはない、本発明1116～1119のいずれかの方法。
[本発明1121]
前記解離が、T細胞における刺激シグナルを終結または軽減させる、本発明1116～1120のいずれかの方法。
[本発明1122]
競合試薬および遊離結合剤が、独立して、ストレプトアビジン結合分子;ビオチン;D-ビオチン;ビオチン類似体;ストレプトアビジン、または野生型ストレプトアビジンの位置44～47に対応する配列位置にアミノ酸配列Val
44
-Thr
45
-Ala
46
-Arg
47
もしくはIle
44
-Gly
45
-Ala
46
-Arg
47
を有するストレプトアビジン類似体に特異的に結合するビオチン類似体からなる群からの分子を含むか、または
競合試薬および遊離結合剤が、独立して、任意でEDTAまたはEGTAである、金属キレート剤を含む、
本発明1116～1121のいずれかの方法。
[本発明1123]
競合試薬および遊離結合剤が、独立して、D-ビオチン、任意で1mMのD-ビオチンを含む、本発明1116～1122のいずれかの方法。
[本発明1124]
細胞を洗浄する工程をさらに含み、任意で、該洗浄工程が組成物中の刺激試薬および/または1つもしくは複数の刺激物質を低減または除去する、本発明1081～1123のいずれかの方法。
[本発明1125]
洗浄する工程が採取前に実行される、本発明1124の方法。
[本発明1126]
T細胞が、抗原特異的T細胞もしくはその集団、Tヘルパー細胞もしくはその集団、細胞傷害性T細胞もしくはその集団、メモリーT細胞もしくはその集団、または制御性T細胞もしくはその集団を含む、本発明1001～1125のいずれかの方法。
[本発明1127]
T細胞がCD3＋T細胞を含むか、CD4＋および/またはCD8＋T細胞を含む、本発明1001～1126のいずれかの方法。
[本発明1128]
前記組成物の刺激されたT細胞からT細胞サブセットを選択する工程を含み、その後に本発明1081～1093のいずれかの導入が行われ、選択された該T細胞サブセットに組換え核酸分子が導入される、本発明1001～1127のいずれかの方法。
[本発明1129]
形質導入細胞を含む組成物からT細胞サブセットを選択する工程を含み、その後に本発明1094～1099のいずれかのインキュベーションが行われ、選択された該T細胞サブセットがウイルス組込みのための条件下でインキュベートされる、本発明1001～1128のいずれかの方法。
[本発明1130]
操作された細胞を含む組成物からT細胞サブセットを選択する工程を含み、その後に本発明1100～1101のいずれかの培養工程が行われ、選択された該T細胞サブセットが、T細胞を拡大培養するための条件下で培養される、本発明1001～1129のいずれかの方法。
[本発明1131]
操作された細胞を含む組成物からT細胞サブセットを選択する工程を含み、その後に本発明1102～1109のいずれかの採取が行われ、選択された該T細胞サブセットが、操作されたT細胞のアウトプット集団を作製するために採取される、本発明1001～1130のいずれかの方法。
[本発明1132]
T細胞サブセットがナイーブ様T細胞であるか、またはナイーブ様T細胞上に発現するマーカーについて表面陽性であるT細胞がCCR7＋CD45RA＋、CD27＋CCR7＋もしくはCD62L-CCR7＋である、本発明1129～1131のいずれかの方法。
[本発明1133]
ナイーブ様T細胞がCD27＋CCR7＋T細胞を含む、本発明1129または本発明1132の方法。
[本発明1134]
ナイーブ様T細胞がCCR7＋CD45RA＋T細胞を含む、本発明1129または本発明1132の方法。
[本発明1135]
T細胞サブセットが、組換えタンパク質、任意でキメラ抗原受容体を発現する、本発明1129～1134のいずれかの方法。
[本発明1136]
T細胞サブセットを選択する工程がアフィニティーカラムクロマトグラフィーによって実行される、本発明1129～1135のいずれかの方法。
[本発明1137]
採取された細胞を、冷凍保存用および/または対象への投与用に、任意で薬学的に許容される賦形剤の存在下で、製剤化する工程をさらに含む、本発明1102～1108、1125および1129～1136のいずれかの方法。
[本発明1138]
採取された細胞が凍結保護物質の存在下で製剤化される、本発明1102～1108、1125および1129～1137のいずれかの方法。
[本発明1139]
固定相がクロマトグラフィーマトリックスであるか、またはそれを含む、本発明1001～1138のいずれかの方法。
[本発明1140]
固定相が、固定相1mLあたりT細胞約7500万～約1億2500万個の結合容量、任意で静的結合容量または動的結合容量を有する、本発明1001～1139のいずれかの方法。
[本発明1141]
（a）固定相が約20mLであり、および/または
（b）固定相が細胞20億±5億個の結合容量を有する、
本発明1001～1140のいずれかの方法。
[本発明1142]
2つの固定相を含む、本発明1001～1141のいずれかの方法。
[本発明1143]
2つの固定相が並列に配置される、本発明1142の方法。
[本発明1144]
2つの固定相が逐次的に配置される、本発明1142の方法。
[本発明1145]
（a）T細胞表面上の第1分子および第2分子にそれぞれ特異的に結合することによってT細胞を刺激する能力を有する、第1刺激物質および第2刺激物質と、
（b）T細胞上の選択マーカーに特異的に結合することによって固定相上にT細胞を固定化する能力を有する選択物質を含む、固定相と
を含む、T細胞のオンカラム刺激のための製造物品。
[本発明1146]
固定相が第1刺激物質および第2刺激物質をさらに含む、本発明1145の製造物品。
[本発明1147]
第1刺激物質、第2刺激物質および選択物質が、選択試薬を介して間接的に固定相に結合されている、本発明1145または本発明1146の製造物品。
[本発明1148]
刺激試薬をさらに含み、第1刺激物質および第2刺激物質が、可逆的に結合されているかまたは可逆的に結合される能力を有する、本発明1145の製造物品。
[本発明1149]
選択物質が選択試薬を介して間接的に固定相に結合されている、本発明1145の製造物品。
[本発明1150]
固定相が、クロマトグラフィーマトリックスであるかそれを含み、前記製造物品が、該クロマトグラフィーマトリックスの全部または一部を含有する容器をさらに含む、本発明1145～1149のいずれかの製造物品。
[本発明1151]
2つの固定相を含む、本発明1145～1150のいずれかの製造物品。
[本発明1152]
2つの固定相が並列に配置される、本発明1151の製造物品。
[本発明1153]
2つの固定相が逐次的に配置される、本発明1151の製造物品。
[本発明1154]
本発明1145～1153のいずれかの製造物品を含む、装置。
[本発明1155]
装置の1つまたは複数の構成要素に流体的に接続された流体入口および/あるいは装置の1つまたは複数の構成要素に流体的に接続された流体出口をさらに含む、本発明1154の装置。
[本発明1156]
閉鎖システム内または無菌システム内にある、本発明1154または1155のいずれかの装置。
[本発明1157]
自動で実行されてもよい本発明1001～1144のいずれかの方法において使用するための、本発明1154～1156のいずれかの装置または本発明1145～1153のいずれかの物品。
Apparatus and/or articles of manufacture are provided for use in any of the methods provided herein (including aspects thereof) that may be performed automatically.
[Invention 1001]
A method for on-column stimulation of T cells comprising the following steps:
Adding an oligomeric stimulating reagent having the ability to deliver stimulatory signals in T cells to a stationary phase comprising a plurality of immobilized T cells, thereby initiating incubation of the stimulating reagent with one or more T cells. and
said stationary phase comprises a selection agent that specifically binds to a selection marker on the surface of one or more T cells or subsets thereof;
wherein said oligomeric stimulatory reagent comprises one or more stimulatory substances comprising (i) a first stimulatory substance that is an anti-CD3 antibody and (ii) a second stimulatory substance that is an anti-CD28 antibody;
process; and
Collecting one or more of said plurality of T cells from said stationary phase by gravity flow within 24 hours of initiating incubation, thereby producing a composition comprising stimulated T cells.
[Invention 1002]
A method for on-column stimulation of T cells comprising the following steps:
(a) incubating a plurality of T cells immobilized on a stationary phase with one or more stimulating agents to deliver a stimulatory signal in one or more T cells of the plurality of T cells; wherein said stationary phase comprises a selection agent that specifically binds to a selectable marker on the surface of said one or more T cells to said selectable marker expressed by said one or more T cells specific binding of said selective agent of immobilizes said one or more T cells onto said stationary phase; and
(b) collecting said one or more T cells from said stationary phase by gravity flow within 24 hours of the start of incubation, thereby producing a composition comprising stimulated T cells.
[Invention 1003]
The stationary phase comprises at least one of one or more stimulatory substances capable of delivering a stimulatory signal in one or more T cells, or comprises at least one of said one or more stimulatory substances. The method of the invention 1002, immobilized together.
[Invention 1004]
The one or more stimulating substances are a primary stimulating substance and a secondary stimulating substance, including a secondary stimulating substance capable of enhancing, attenuating or modifying the stimulating signal of the first stimulating substance prior to incubation. 1002. The method of the invention 1002, wherein a stimulating reagent is added to the stationary phase.
[Invention 1005]
The method of invention 1002, comprising adding a stimulating reagent comprising at least one of the one or more stimulating substances to the stationary phase prior to incubating.
[Invention 1006]
The present invention 1005 wherein at least one stimulating substance is a primary stimulating substance and the one or more stimulating substances further comprises a second stimulating substance capable of enhancing, attenuating or modifying the stimulatory signal of the first stimulating substance the method of.
[Invention 1007]
at least one of the one or more stimulating agents, optionally the first stimulating agent, has the ability to deliver a stimulatory signal, which stimulates the TCR/CD3 complex in T cells, 1006. The method of any of the inventions 1002-1006, wherein the stimulatory signal is through a CD3-containing complex of and/or ITAM-containing molecules in T cells.
[Invention 1008]
The method of any of inventions 1004, 1006 and 1007, wherein the second stimulatory agent has the ability to specifically bind to one or more co-stimulatory molecules on T cells.
[Invention 1009]
A method for on-column stimulation of T cells comprising the following steps:
(a) adding a sample comprising a plurality of T cells to a stationary phase, said stationary phase comprising a selection agent that binds to a selectable marker on the surface of one or more of said plurality of T cells; , whereby said one or more of a plurality of T cells are immobilized on said stationary phase;
(b) adding to said stationary phase a stimulating reagent comprising one or more stimulating substances capable of delivering a stimulating signal in one or more of said plurality of T cells, whereby said stimulating reagent and said initiating incubation with one or more T cells; and
(c) collecting one or more of said plurality of T cells from said stationary phase by gravity flow within 24 hours of initiation of incubation, thereby producing a composition comprising stimulated T cells; .
[Invention 1010]
A method for on-column stimulation of T cells comprising the following steps:
(1) (a) a sample comprising a plurality of T cells and (b) an immobilization comprising a selection agent capable of specifically binding to one or more surface-expressed selectable markers of the plurality of T cells phase, wherein specific binding of the selection agent to the selectable marker immobilizes the one or more of the plurality of T cells to the stationary phase;
(2) adding a stimulating reagent comprising one or more stimulating substances capable of delivering stimulatory signals in T cells to said stationary phase, thereby incubating said stimulating reagent with said one or more T cells; initiating; and
(3) collecting one or more of said plurality of T cells from said stationary phase by gravity flow within 24 hours of initiation of incubation, thereby producing a composition comprising stimulated T cells; .
[Invention 1011]
A method for on-column stimulation of T cells comprising the following steps:
adding an oligomeric stimulating reagent to a stationary phase comprising a plurality of immobilized T cells, thereby initiating incubation of said stimulating reagent with one or more T cells of said plurality of immobilized T cells. There is
The stationary phase comprises a selection agent that specifically binds to a selectable marker on the surface of one or more T cells, and binding the selectable agent to the selectable marker expressed by the one or more T cells. specific binding immobilizes said one or more T cells to said stationary phase;
said oligomeric stimulatory reagent comprises (i) a plurality of streptavidin molecules or streptavidin mutein molecules and (ii) one or more stimulatory agents capable of delivering a stimulatory signal in one or more T cells; The size of said oligomeric stimulating reagent is (i) a radius greater than 50 nm, (ii) a molecular weight of at least 5 x 106 g/mol and/or (iii) at least 100 streptavidin tetramers or strepts per oligomeric stimulating reagent. comprising an avidin mutein tetramer,
process.
[Invention 1012]
within 24 hours of initiating the incubation, collecting one or more of the plurality of T cells from the stationary phase by gravity flow, thereby producing a composition comprising the stimulated T cells. The method of invention 1011.
[Invention 1013]
Collecting one or more of the plurality of T cells from the stationary phase is about 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11 from the start of the incubation. The method of any of the inventions 1001-1010 or 1012, wherein the method is performed within 10, 9, 8, 7, 6, 5, 4, 3 or 2 hours.
[Invention 1014]
Collecting one or more of the plurality of T cells from the stationary phase is about 2-24, 3-24, 4-24, 5-24, 6-24, 7-24, 8- 24, 9-24, 10-24, 11-24, 12-24, 13-24, 14-24, 15-24, 16-24, 17-24, 18-24, 19-24, 20-24, 21-24, 22-24, 23-24, 2-23, 2-22, 2-21, 2-20, 2-19, 2-18, 2-17, 2-16, 2-15, 2- Within 14, 2-13, 2-12, 2-11, 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, or 2-3 hours , the method of any of 1001-1010, 1012 or 1013 of the present invention.
[Invention 1015]
1001-1010 or 1012-1014 of the invention wherein collecting one or more of the plurality of T cells from the stationary phase is performed within about 12, 10, 8, 6, 4 or 2 hours from the start of the incubation Either method.
[Invention 1016]
The method of any of invention 1001-1010 or 1012-1015, wherein collecting one or more of the plurality of T cells from the stationary phase occurs within 5 hours of starting the incubation.
[Invention 1017]
The method of any of invention 1001-1010 or 1012-1016, wherein collecting one or more of the plurality of T cells from the stationary phase occurs within or about 4.5 hours from initiation of incubation.
[Invention 1018]
The method of any of invention 1001-1010 or 1012-1017, wherein collecting one or more of the plurality of T cells from the stationary phase occurs within 4 hours of starting the incubation.
[Invention 1019]
start of incubation with the stimulating reagent is within or about 10 minutes or less, within or about 20 minutes or less after adding the sample containing the plurality of T cells to the stationary phase or after mixing with the stationary phase; minutes or less or about 30 minutes or less, 45 minutes or less or about 45 minutes or less, 60 minutes or less or about 60 minutes or less, 90 minutes or less or about 90 minutes or less, or 120 minutes or less or about 120 minutes or less, the present invention Any of the methods 1001, 1009, 1010 and 1013-1017.
[Invention 1020]
The present invention 1001, 1009, wherein the initiation of incubation with the stimulating reagent is performed within or about 60 minutes after adding or mixing the sample containing the plurality of T cells to the stationary phase. Any method from 1010 and 1013-1019.
[Invention 1021]
at least one of the one or more stimulatory agents has the ability to deliver a stimulatory signal, which is activated by a TCR/CD3 complex in T cells, a CD3-containing complex in T cells and/or 1020. The method of any of the inventions 1009-1020, wherein the stimulatory signal is mediated by ITAM-containing molecules in T cells.
[Invention 1022]
The present invention wherein at least one stimulating substance is a primary stimulating substance and the stimulating reagent further comprises one or more of a second stimulating substance capable of enhancing, attenuating or modifying the stimulating signal of the first stimulating substance. The method of invention 1021.
[Invention 1023]
The method of any of inventions 1004, 1006, 1007 and 1022, wherein the second stimulatory agent has the ability to specifically bind to one or more co-stimulatory molecules on T cells.
[Invention 1024]
The subject, wherein the co-stimulatory molecule is selected from CD28, CD90 (Thy-1), CD95 (Apo-/Fas), CD137 (4-1BB), CD154 (CD40L), ICOS, LAT, CD27, OX40 or HVEM The method of invention 1008 or invention 1023.
[Invention 1025]
The method of invention 1008, invention 1023 or invention 1024, wherein the second stimulatory agent has the ability to specifically bind to CD28 and/or the co-stimulatory molecule is CD28.
[Invention 1026]
The method of any of the inventions 1014, 1006, 1007, 1008 and 1020-1023, wherein the first stimulating agent specifically binds CD3 and the second stimulating agent specifically binds CD28.
[Invention 1027]
The one or more stimulating agents are independently antibody fragments, monovalent antibody fragments, proteinaceous binding molecules with immunoglobulin-like function, molecules containing Ig domains, cytokines, chemokines, aptamers, MHC molecules, MHC- is or comprises a substance selected from the group consisting of peptide conjugates; receptor ligands; and binding fragments thereof;
The method of any of inventions 1001-1026.
[Invention 1028]
The first stimulating substance and the second stimulating substance are independently antibody fragments, monovalent antibody fragments, proteinaceous binding molecules with immunoglobulin-like functions, Ig domain-containing molecules, cytokines, chemokines, aptamers, MHC molecules, is or comprises a substance selected from the group consisting of MHC-peptide complexes; receptor ligands; and binding fragments thereof;
The method of any of the inventions 1004, 1006, 1007, 1008 or 1013-1020, 1022-1264.
[Invention 1029]
The method of any of inventions 1001-1027, wherein the one or more stimulating agents comprises a monovalent antibody fragment.
[Invention 1030]
The method of any of the inventions 1001, 1004, 1006, 1007, 1008, 1013-1020, 1022-1026 and 1028, wherein the first stimulating agent and the second stimulating agent independently comprise monovalent antibody fragments.
[Invention 1031]
the invention 1001, 1004, 1006, 1007, 1008, 1013-1020, wherein the first stimulating agent comprises a monovalent antibody fragment that binds to CD3 and the second stimulating agent comprises a monovalent antibody fragment that binds to CD28; Any method from 1022-1026, 1028 and 1030.
[Invention 1032]
The method of any one of Inventions 1027-1031, wherein the monovalent antibody fragment is selected from the group consisting of Fab fragments, Fv fragments and single chain Fv fragments (scFv).
[Invention 1033]
Any of the invention 1001, 1004, 1006, 1007, 1008, 1013-1020, 1022-1026, 1028 and 1030-1032, wherein the first stimulator is an anti-CD3 Fab and the second stimulator is an anti-CD28 Fab the method of.
[Invention 1034]
A method for on-column stimulation of T cells comprising the following steps:
Adding an oligomeric stimulating reagent having the ability to deliver stimulatory signals in T cells to a stationary phase comprising a plurality of immobilized T cells, thereby initiating incubation of the stimulating reagent with one or more T cells. and
said stationary phase comprises a selection agent capable of specifically binding to a selectable marker on the surface of one or more T cells or subsets thereof, expressed by said one or more T cells or subsets thereof Specific binding of said selection agent to a selectable marker immobilizes said at least a plurality of T cells to said stationary phase, said selection agent specifically binding to a selectable marker selected from the group consisting of CD3, CD4 and CD8. is a Fab fragment that has the ability to
The oligomeric stimulatory reagent is (i) a plurality of streptavidin mutein molecules, (ii) a Fab fragment capable of specifically binding to CD3 and capable of delivering a stimulatory signal in one or more T cells. and (iii) a Fab fragment capable of specifically binding CD28 and capable of enhancing, attenuating or altering the stimulatory signal, the oligomeric stimulating reagent having a size of , (i) a radius greater than 50 nm, (ii) a molecular weight of at least 5×10 6 g/mol, and/or (iii) at least 100 streptavidin tetramers or streptavidin mutein tetramers per oligomer stimulating reagent. include,
process; and
Collecting one or more of said plurality of T cells from said stationary phase by gravity flow within 24 hours of initiating incubation, thereby producing a composition comprising stimulated T cells.
[Invention 1035]
T cells are or contain whole blood samples, buffy coat samples, peripheral blood mononuclear cell (PBMC) samples, unfractionated T cell samples, lymphocyte samples, leukocyte samples, apheresis products or leukoapheresis products The method of any of the inventions 1001-1034 derived from.
[Invention 1036]
1035. The method of any of invention 1035, wherein the sample is an apheresis product or a leukoapheresis product.
[Invention 1037]
1036. The method of any of invention 1036, wherein the apheresis product or leukoapheresis product has been previously cryofrozen.
[Invention 1038]
The method of any of the inventions 1002-1027 and 1029, wherein incubating with one or more stimulating agents releases one or more of the plurality of immobilized T cells from the stationary phase.
[Invention 1039]
1001, 1004, 1006, 1007, 1008, 1013-1020 of the invention wherein incubating with the first stimulating agent and the second stimulating agent releases one or more of the plurality of immobilized T cells from the stationary phase , 1022-1026, 1028, 1030-1038.
[Invention 1040]
biotin analogues in which one or more stimulating substances reversibly bind to biotin, streptavidin or avidin;
[Invention 1041]
one or more irritants,
[Invention 1042]
One or more stimulants are present in the sequence
[Invention 1043]
biotin analogues in which the first stimulator and the second stimulator independently reversibly bind to biotin, streptavidin or avidin;
[Invention 1044]
Each of the first stimulus and the second stimulus is
[Invention 1045]
Each of the first stimulator and the second stimulator comprises the sequence
[Invention 1046]
the selected agent is antibody fragments, monovalent antibody fragments, proteinaceous binding molecules with immunoglobulin-like function, molecules containing Ig domains, cytokines, chemokines, aptamers, MHC molecules, MHC-peptide complexes; receptor ligands; The method of any of inventions 1001-1045 which is or comprises a substance selected from the group consisting of binding fragments thereof.
[Invention 1047]
the selectable marker is a T cell co-receptor;
the selectable marker is or comprises a member of the T cell antigen receptor complex;
the selectable marker is or comprises a CD3 chain;
the selectable marker is or comprises the CD3 zeta chain;
the selectable marker is or contains CD8;
the selectable marker is or comprises CD4;
the selectable marker is or contains CD45RA;
the selectable marker is or comprises CD27;
the selectable marker is or comprises CD28 and/or
the selectable marker is or contains CCR7;
The method of any of Inventions 1001-1046.
[Invention 1048]
The method of any of inventions 1001-1047, wherein the selectable marker is selected from the group consisting of CD3, CD4 and CD8.
[Invention 1049]
The method of any of inventions 1001-1048, wherein the selectable marker is CD3.
[Invention 1050]
a biotin analogue in which the agent of choice reversibly binds to biotin, streptavidin or avidin;
[Invention 1051]
a biotin analogue in which the agent of choice reversibly binds to biotin, streptavidin or avidin;
[Invention 1052]
the selected substance is the sequence
[Invention 1053]
of the invention 1001-1052, wherein the specific binding between the selectable agent and the selectable marker does not induce a signal to T cells, or any stimulatory, activating or proliferative signals to T cells. either way.
[Invention 1054]
The method of any of inventions 1001-1053, wherein the selection agent comprises a monovalent antibody fragment that binds CD3, CD8 or CD4.
[Invention 1055]
The method of any of inventions 1001-1054, wherein the selection agent is an anti-CD3 Fab, an anti-CD8 Fab or an anti-CD4 Fab.
[Invention 1056]
The method of any of inventions 1001-1055, wherein the selection agent is an anti-CD3 Fab.
[Invention 1057]
The stimulating reagent is an oligomeric stimulating reagent comprising a plurality of streptavidin molecules or streptavidin mutein molecules, wherein the oligomeric particle reagent has a size of (i) a radius greater than 50 nm, (ii) at least 5×10 6 g/mol. The method of any of invention 1004-1010, 1013-1033 and 1035-1056 comprising at least 100 streptavidin tetramers or streptavidin mutein tetramers per molecular weight and/or (iii) oligomeric stimulating reagent.
[Invention 1058]
The oligomeric stimulating reagent comprises a plurality of streptavidin molecules or streptavidin mutein molecules, and the size of the oligomeric particle reagent is (i) a radius greater than 50 nm, (ii) a molecular weight of at least 5×10 6 g/mol and/or (iii) The method of invention 1001 comprising at least 100 streptavidin tetramers or streptavidin mutein tetramers per oligomeric stimulating reagent.
[Invention 1059]
The method of any of invention 1001, 1011-1058, wherein the oligomeric stimulating reagent is soluble.
[Invention 1060]
the oligomeric stimulating reagent is not and is not bound to or associated with a solid support, stationary phase, bead, microparticle, magnetic particle and/or matrix, and/or
the reagent is flexible, contains no metallic or magnetic core, is composed entirely or primarily of organic polymers, and/or is not rigid;
The method of any one of the inventions 1001, 1011-1059.
[Invention 1061]
1060. The method of any of the inventions 1011-1060, wherein the streptavidin molecule or streptavidin mutein molecule reversibly binds or has the ability to reversibly bind biotin, a biotin analogue or a streptavidin-binding peptide.
[Invention 1062]
The streptavidin mutein comprises the amino acid sequence Ile 44 -Gly 45 -Ala 46 -Arg 47 at sequence positions corresponding to positions 44-47 relative to positions in streptavidin in the sequence of amino acids shown in SEQ ID NO:1 or
The streptavidin mutein comprises the amino acid sequence Val 44 -Thr 45 -Ala 46 -Arg 47 at sequence positions corresponding to positions 44-47 relative to positions in streptavidin in the sequence of amino acids shown in SEQ ID NO:1 ,
The method of any of Inventions 1011-1061.
[Invention 1063]
A streptavidin-binding peptide
[Invention 1064]
the oligomer stimulating reagent is
Radius greater than 60nm, greater than 70nm, greater than 80nm or greater than 90nm
The method of any of inventions 1001 and 1011-1063, comprising:
[Invention 1065]
the oligomer stimulating reagent is
Radius from 50 nm to 150 nm, 75 nm to 125 nm, 80 nm to 115 nm, or 90 nm to 110 nm, inclusive, or
Radius of 90nm±15nm or 95nm±20~25nm
The method of any of the inventions 1001 and 1011-1064, comprising:
[Invention 1066]
1164. The method of any of invention 1164, wherein said radius is a hydrodynamic radius.
[Invention 1067]
the oligomer stimulating reagent is
at least 5 x 107 g/mol or at least 1 x 108 g/mol, and/or
5×10 7 g/mol to 5×10 8 g/mol, 1×10 8 g/mol to 5×10 8 g/mol, or 1×10 8 g/mol to 2×10 8 g/mol
The method of any of the present invention 1001 and 1011-1066, comprising a molecular weight of
[Invention 1068]
the oligomer stimulating reagent is
at least 500 streptavidin tetramers or streptavidin mutein tetramers, at least 1,000 streptavidin tetramers or streptavidin mutein tetramers, at least 1,500 streptavidin tetramers or streptavidin mutein tetramers , or at least 2,000 streptavidin tetramers or streptavidin mutein tetramers, and/or
1,000-20,000 streptavidin tetramers or streptavidin mutein tetramers, 1,000-10,000 streptavidin tetramers or streptavidin mutein tetramers, or 2,000-5,000 streptavidin tetramers or streptavidin mutein tetramer
The method of any of inventions 1001 and 1011-1067, comprising:
[Invention 1069]
The method of any of inventions 1001 and 1011-1068, wherein the oligomeric stimulating reagent is added to the stationary phase at a concentration of about 1 to about 2 μg/million cells.
[Invention 1070]
The method of any of inventions 1001-1069, wherein the selection agent is attached directly or indirectly to the stationary phase.
[Invention 1071]
1070. The method of any of inventions 1001-1070, wherein the selection agent is indirectly bound to the stationary phase via a selection reagent to which the selection agent is reversibly bound.
[Invention 1072]
a mutein of streptavidin that reversibly binds to biotin, a biotin analog or a biologically active fragment thereof; avidin or streptavidin that reversibly binds to a streptavidin-binding peptide; muteins; reagents comprising at least two chelating groups K, wherein said at least two chelating groups are capable of binding transition metal ions; substances capable of binding oligohistidine affinity tags; glutathione-S Calmodulin or an analogue thereof; A substance capable of binding calmodulin binding peptide (CBP); A substance capable of binding FLAG peptide; A substance capable of binding HA tag; a substance capable of binding maltose binding protein (MBP); a substance capable of binding an HSV epitope; a substance capable of binding a myc epitope; or a substance capable of binding a biotinylated carrier protein, or or a method of the invention 1070 or the invention 1071 comprising the same.
[Invention 1073]
the selection reagent is or comprises a streptavidin or avidin mutein that reversibly binds to biotin or a biologically active fragment;
the stimulating reagent is or comprises a streptavidin or avidin mutein that reversibly binds to a biotin analogue or biologically active fragment, and/or
the stimulating reagent is or comprises a streptavidin or avidin mutein that reversibly binds to a streptavidin-binding peptide;
The method of any of the inventions 1070-1072.
[Invention 1074]
A method of Invention 1072 or Invention 1073, wherein the streptavidin molecule or streptavidin mutein molecule reversibly binds or has the ability to reversibly bind biotin, a biotin analogue or a streptavidin-binding peptide.
[Invention 1075]
The streptavidin mutein comprises the amino acid sequence Ile 44 -Gly 45 -Ala 46 -Arg 47 at sequence positions corresponding to positions 44-47 relative to positions in streptavidin in the sequence of amino acids shown in SEQ ID NO:1 or
The streptavidin mutein comprises the amino acid sequence Val 44 -Thr 45 -Ala 46 -Arg 47 at sequence positions corresponding to positions 44-47 relative to positions in streptavidin in the sequence of amino acids shown in SEQ ID NO:1 ,
The method of any of the inventions 1072-1074.
[Invention 1076]
A streptavidin-binding peptide
[Invention 1077]
A streptavidin-binding peptide has the sequence
[Invention 1078]
1001-1010 or 1012- of the invention, wherein the collecting by gravity flow comprises adding to the stationary phase a medium containing neither a competitor nor a free binding agent to elute the T cells from the stationary phase. 1077 either way.
[Invention 1079]
The method of any of the inventions 1001-1010 and 1012-1078, wherein the composition comprising the stimulated T cells does not contain competitors or free binding agents.
[Invention 1080]
The method of invention 1078 or 1079, wherein the competitor or free binding agent is or comprises biotin or a biotin analogue, optionally wherein the biotin analogue is D-biotin.
[Invention 1081]
introducing a recombinant nucleic acid molecule encoding a recombinant protein into the stimulated T cells of said composition, thereby producing a composition comprising the engineered T cell, optionally the transduced T cell The method of any of inventions 1001-1078, further comprising the step of:
[Invention 1082]
The method of invention 1081, wherein the recombinant protein is an antigen receptor.
[Invention 1083]
The method of invention 1081 or invention 1082, wherein the recombinant protein is a chimeric antigen receptor.
[Invention 1084]
1083. The method of invention 1083, wherein the chimeric antigen receptor (CAR) comprises an extracellular antigen recognition domain that specifically binds to a target antigen and an intracellular signaling domain comprising an ITAM.
[Invention 1085]
1084. The method of invention 1084, wherein the intracellular signaling domain comprises the intracellular domain of the CD3 zeta (CD3ζ) chain.
[Invention 1086]
The method of invention 1084 or invention 1085 further comprising a transmembrane domain linking the extracellular domain and the intracellular signaling domain.
[Invention 1087]
The method of invention 1086, wherein the transmembrane domain comprises a transmembrane portion of CD28.
[Invention 1088]
The method of any of inventions 1084-1087, wherein the intracellular signaling domain further comprises an intracellular signaling domain of a T cell co-stimulatory molecule.
[Invention 1089]
1088. The method of invention 1088, wherein the T cell co-stimulatory molecule is selected from the group consisting of CD28 and 41BB.
[Invention 1090]
The method of any of inventions 1081-1089, wherein said nucleic acid further comprises a promoter operably linked to the nucleic acid encoding the recombinant antigen receptor.
[Invention 1091]
The method of any of inventions 1081-1090, wherein introduction of the recombinant nucleic acid is accomplished by transduction using viral particles.
[Invention 1092]
1091. The method of invention 1091, wherein the viral particles are retroviral vector particles.
[Invention 1093]
The method of Invention 1091 or Invention 1092, wherein the viral particles are lentiviral vector particles.
[Invention 1094]
Any of inventions 1081-1093, further comprising incubating the composition comprising the transduced cells under conditions for viral integration, optionally at or at a temperature of 37°±2° C. or about 37°±2° C. the method of.
[Invention 1095]
1094. The method of the invention 1094, wherein the step of incubating the composition comprising the transduced cells is performed for up to 96 hours after introduction.
[Invention 1096]
1094. The method of the invention 1094, wherein the step of incubating the composition comprising the transduced cells is performed for up to 72 hours after introduction.
[Invention 1097]
1094. The method of the invention 1094, wherein the step of incubating the composition comprising the transduced cells is performed for up to 48 hours after introduction.
[Invention 1098]
1094. The method of invention 1094, wherein the step of incubating the composition comprising the transduced cells is carried out for up to 24 hours after introduction.
[Invention 1099]
The method of any of inventions 1094-1098, wherein the step of incubating the composition comprising the transduced cells is performed for at least 18 hours after introduction.
[Invention 1100]
The method of any of inventions 1081-1099, further comprising culturing the composition comprising the engineered cells, optionally the transduced cells, under conditions for T cell expansion.
[Invention 1101]
The method of the invention 1100, wherein the culturing is performed for a period of 14 days or less, 12 days or less, 10 days or less, 8 days or less, 6 days or less, or 5 days or less.
[Invention 1102]
The method of any of inventions 1081-1101, further comprising harvesting the engineered T cells, thereby generating an output population of engineered T cells.
[Invention 1103]
The method of any of Inventions 1081-1099, further comprising harvesting the engineered T cells at 48-120 hours, inclusive, after exposure to the stimulating reagent begins.
[Invention 1104]
The method of any of the inventions 1081-1099 and 1103, wherein harvesting is performed within 120 hours after exposure to the stimulus is initiated.
[Invention 1105]
The method of any of the inventions 1081-1099 and 1103, wherein harvesting is performed within 96 hours after exposure to the stimulus is initiated.
[Invention 1106]
The method of any of the inventions 1081-1099 and 1105, wherein harvesting is performed within 72 hours after initiation of exposure to the stimulant.
[Invention 1107]
The method of any of the inventions 1081-1099 and 1106, wherein harvesting is performed within 48 hours after initiation of exposure to the stimulant.
[Invention 1108]
Percentage of naive-like cells greater than or about 60% of total T cells in the population, total CD4+ T cells in the population, or total CD8+ T cells or recombinant protein-expressing cells thereof in the population at the time of collection The method of any of inventions 1102-1107 which is super.
[Invention 1109]
1108. The method of invention 1108, wherein the naive-like T cells comprise CD27+CCR7+ cells.
[Invention 1110]
The method of any of inventions 1081-1093, wherein the introduction is carried out in serum-free medium.
[Invention 1111]
The method of any of inventions 1094-1099, wherein the incubating step is performed in serum-free medium.
[Invention 1112]
The method of invention 1100 or invention 1101, wherein the step of culturing is performed in serum-free medium.
[Invention 1113]
serum-free medium
0.5 mM to 5 mM dipeptide L-glutamine in basal medium;
0.5 mM to 5 mM L-glutamine, and
optionally at least one protein
and wherein said medium does not contain serum.
[Invention 1114]
The serum-free medium contains recombinant cytokines selected among IL-2, IL-15 and IL-7, optionally recombinant human IL-2, recombinant human IL-15 and/or recombinant human IL- The method of any of Inventions 1110-1113, including 7.
[Invention 1115]
The serum-free medium contains recombinant cytokines selected among IL-2, IL-15 and IL-7, optionally recombinant human IL-2, recombinant human IL-15 and/or recombinant human IL- The method of any of Inventions 1110-1114 that does not include 7.
[Invention 1116]
further comprising the step of adding a competitor or free binding agent to the composition comprising the engineered cells, optionally comprising the transduced T cells, optionally wherein said agent induces one or more stimulatory agents into said composition; The method of any of Inventions 1081-1093, added under conditions to dissociate from the oligomeric stimulating reagent in the product.
[Invention 1117]
further adding a competitor or free binding agent to the composition comprising the incubated T cells, optionally under conditions to dissociate the one or more stimulating agents from the oligomeric stimulating reagents in the composition. The method of any of the inventions 1094-1099, comprising:
[Invention 1118]
further adding a competitor or free binding agent to the composition comprising the cultured T cells, optionally under conditions to dissociate the one or more stimulating agents from the oligomeric stimulating reagents in the composition. The method of any of the inventions 1100-1101, comprising:
[Invention 1119]
The method of any of inventions 1116-1118, wherein the step of adding competitor or free binding agent is performed prior to harvesting.
[Invention 1120]
Competitor or free binding agent is not toxic to T cells and/or addition of said substance compared to incubation of T cells under equivalent or identical conditions without said competitor or said free binding agent and does not reduce the percentage of surviving T cells to less than 90%, less than 80%, less than 70%, less than 60% or less than 50%.
[Invention 1121]
The method of any of the inventions 1116-1120, wherein said dissociation terminates or reduces stimulatory signals in T cells.
[Invention 1122]
biotin; D-biotin; biotin analog; streptavidin; comprising a molecule from the group consisting of a biotin analogue that specifically binds to a streptavidin analogue having -Thr45 - Ala46 - Arg47 or Ile44- Gly45 - Ala46 - Arg47 , or
including metal chelators, wherein the competing reagent and the free binding agent are independently optionally EDTA or EGTA;
The method of any of the inventions 1116-1121.
[Invention 1123]
The method of any of inventions 1116-1122, wherein the competing reagent and free binding agent independently comprise D-biotin, optionally 1 mM D-biotin.
[Invention 1124]
The method of any of inventions 1081-1123, further comprising washing the cells, optionally wherein said washing step reduces or eliminates the stimulatory reagent and/or one or more stimulatory substances in the composition.
[Invention 1125]
The method of the invention 1124, wherein washing is performed prior to harvesting.
[Invention 1126]
1001 of the present invention, wherein the T cells comprise antigen-specific T cells or populations thereof, T helper cells or populations thereof, cytotoxic T cells or populations thereof, memory T cells or populations thereof, or regulatory T cells or populations thereof Any method from ~1125.
[Invention 1127]
The method of any of invention 1001-1126, wherein the T cells comprise CD3+ T cells, or comprise CD4+ and/or CD8+ T cells.
[Invention 1128]
selecting a T cell subset from the stimulated T cells of said composition, followed by the introduction of any of the inventions 1081-1093, wherein said selected T cell subset is introduced with a recombinant nucleic acid molecule. The method of any of the inventions 1001-1127.
[Invention 1129]
selecting a T cell subset from a composition comprising the transduced cells, followed by incubation of any of the inventions 1094-1099, wherein the selected T cell subset is treated under conditions for viral integration. The method of any of inventions 1001-1128, which is incubated.
[Invention 1130]
comprising the step of selecting a T cell subset from a composition comprising engineered cells, followed by the culturing step of any of the inventions 1100-1101, wherein the selected T cell subset expands into T cells. 1129. The method of any of the inventions 1001-1129, wherein the cultured under conditions to do.
[Invention 1131]
selecting a T cell subset from a composition comprising the engineered cells, followed by harvesting of any of the inventions 1102-1109, wherein the selected T cell subset is a subset of the engineered T cells. The method of any of the inventions 1001-1130 taken to create an output population.
[Invention 1132]
The method of any of the inventions 1129-1131, wherein the T cell subset is naive-like T cells, or the T cells that are surface positive for markers expressed on naive-like T cells are CCR7+CD45RA+, CD27+CCR7+ or CD62L-CCR7+ .
[Invention 1133]
The method of invention 1129 or invention 1132, wherein the naive-like T cells comprise CD27+CCR7+ T cells.
[Invention 1134]
The method of invention 1129 or invention 1132, wherein the naive-like T cells comprise CCR7+CD45RA+ T cells.
[Invention 1135]
The method of any of inventions 1129-1134, wherein the T cell subset expresses a recombinant protein, optionally a chimeric antigen receptor.
[Invention 1136]
The method of any of invention 1129-1135, wherein the step of selecting T cell subsets is performed by affinity column chromatography.
[Invention 1137]
The invention 1102-1108, 1125 further comprising formulating the harvested cells for cryopreservation and/or for administration to a subject, optionally in the presence of a pharmaceutically acceptable excipient. and any method from 1129-1136.
[Invention 1138]
The method of any of the inventions 1102-1108, 1125 and 1129-1137, wherein the harvested cells are formulated in the presence of a cryoprotectant.
[Invention 1139]
The method of any of inventions 1001-1138, wherein the stationary phase is or comprises a chromatographic matrix.
[Invention 1140]
1139. The method of any of inventions 1001-1139, wherein the stationary phase has a binding capacity of from about 75 million to about 125 million T cells per mL of stationary phase, optionally a static or dynamic binding capacity.
[Invention 1141]
(a) the stationary phase is approximately 20 mL, and/or
(b) the stationary phase has a binding capacity of 2 billion ± 500 million cells,
The method of any of the inventions 1001-1140.
[Invention 1142]
The method of any of inventions 1001-1141 comprising two stationary phases.
[Invention 1143]
The method of invention 1142, wherein two stationary phases are arranged in parallel.
[Invention 1144]
The method of invention 1142, wherein the two stationary phases are arranged sequentially.
[Invention 1145]
(a) a first stimulatory agent and a second stimulatory agent capable of stimulating T cells by specifically binding to a first molecule and a second molecule, respectively, on the T cell surface;
(b) a stationary phase comprising a selective agent capable of immobilizing T cells on the stationary phase by specifically binding to a selectable marker on the T cells;
An article of manufacture for on-column stimulation of T cells comprising:
[Invention 1146]
The article of manufacture of Invention 1145, wherein the stationary phase further comprises a first stimulus and a second stimulus.
[Invention 1147]
The article of manufacture of Invention 1145 or Invention 1146, wherein the first stimulating agent, the second stimulating agent and the selective agent are indirectly bound to the stationary phase via the selective reagent.
[Invention 1148]
The article of manufacture of Invention 1145 further comprising a stimulating reagent, wherein the first stimulating agent and the second stimulating agent are reversibly bound or capable of being reversibly bound.
[Invention 1149]
The article of manufacture of Invention 1145, wherein the selection agent is indirectly attached to the stationary phase via a selection reagent.
[Invention 1150]
The article of manufacture of any of inventions 1145-1149, wherein the stationary phase is or comprises a chromatographic matrix, and wherein said article of manufacture further comprises a vessel containing all or part of said chromatographic matrix.
[Invention 1151]
The article of manufacture of any of inventions 1145-1150 comprising two stationary phases.
[Invention 1152]
The article of manufacture of Invention 1151, wherein the two stationary phases are arranged in parallel.
[Invention 1153]
The article of manufacture of Invention 1151, wherein the two stationary phases are arranged sequentially.
[Invention 1154]
An apparatus comprising the article of manufacture of any of the inventions 1145-1153.
[Invention 1155]
A device of the invention 1154 further comprising a fluid inlet fluidly connected to one or more components of the device and/or a fluid outlet fluidly connected to one or more components of the device.
[Invention 1156]
A device according to any of the inventions 1154 or 1155 in a closed system or in a sterile system.
[Invention 1157]
An apparatus of any of inventions 1154-1156 or an article of any of inventions 1145-1153 for use in any method of any of inventions 1001-1144, which may be performed automatically.
Claims (51)
(a) T細胞において刺激シグナルを送達する能力を有するオリゴマー刺激試薬を、固定相に固定化された複数のT細胞を含む固定相に加え、それによって、該オリゴマー刺激試薬と1つまたは複数のT細胞とのインキュベーションを開始する工程であって、
該固定相が、クロマトグラフィーカラムに含まれ、かつ1つまたは複数のT細胞またはそのサブセットの表面上の選択マーカーに特異的に結合する選択物質を含み、該1つまたは複数のT細胞によって発現された該選択マーカーへの該選択物質の特異的結合が、該1つまたは複数のT細胞を該固定相上に固定化し、
該オリゴマー刺激試薬が、（i）抗CD3抗体または抗体フラグメントである第1刺激物質と（ii）抗CD28抗体または抗体フラグメントである第2刺激物質とを含む1つまたは複数の刺激物質を含む、
工程;および
(b) インキュベーション開始から24時間以内に、該複数のT細胞のうちの1つまたは複数を重力流によって該固定相から収集し、それによって、刺激されたT細胞を含む組成物を生成する工程。 A method for on-column stimulation of T cells comprising the following steps:
(a) adding an oligomeric stimulating reagent having the ability to deliver a stimulatory signal in T cells to a stationary phase comprising a plurality of T cells immobilized on the stationary phase, whereby the oligomeric stimulating reagent and one or more initiating incubation with T cells, comprising:
wherein said stationary phase is contained in a chromatography column and comprises a selection agent that specifically binds to a selectable marker on the surface of one or more T cells or a subset thereof and is expressed by said one or more T cells; specific binding of the selective agent to the selected selectable marker immobilizes the one or more T cells on the stationary phase;
said oligomeric stimulatory reagent comprises one or more stimulatory agents comprising (i) a first stimulatory agent that is an anti-CD3 antibody or antibody fragment and (ii) a second stimulatory agent that is an anti-CD28 antibody or antibody fragment ;
process; and
(b) collecting one or more of said plurality of T cells from said stationary phase by gravity flow within 24 hours of initiation of incubation, thereby producing a composition comprising stimulated T cells; .
（a）固定相上に固定化された複数のT細胞を1つまたは複数の刺激物質と共にインキュベートして、該複数のT細胞のうちの1つまたは複数のT細胞において刺激シグナルを送達する工程であって、該固定相が、クロマトグラフィーカラムに含まれ、かつ該1つまたは複数のT細胞の表面上の選択マーカーに特異的に結合する選択物質を含み、該1つまたは複数のT細胞によって発現された該選択マーカーへの該選択物質の特異的結合が、該1つまたは複数のT細胞を該固定相上に固定化する、工程;および
（b）インキュベーションの開始から24時間以内に、該1つまたは複数のT細胞を重力流によって該固定相から収集し、それによって、刺激されたT細胞を含む組成物を生成する工程。 A method for on-column stimulation of T cells comprising the following steps:
(a) incubating a plurality of T cells immobilized on a stationary phase with one or more stimulating agents to deliver a stimulatory signal in one or more T cells of the plurality of T cells; wherein said stationary phase comprises a selection agent contained in a chromatography column and that specifically binds to a selectable marker on the surface of said one or more T cells, said one or more T cells specific binding of said selection agent to said selectable marker expressed by immobilizes said one or more T cells on said stationary phase; and (b) within 24 hours of initiation of incubation , collecting said one or more T cells from said stationary phase by gravity flow, thereby producing a composition comprising stimulated T cells.
（a）複数のT細胞を含む試料を、クロマトグラフィーカラムに含まれた固定相に加える工程であって、該固定相が、該複数のT細胞のうちの1つまたは複数の表面上の選択マーカーに結合する選択物質を含み、それによって、複数のT細胞のうちの該1つまたは複数が該固定相上に固定化される、工程;
（b）該複数のT細胞のうちの1つまたは複数において刺激シグナルを送達する能力を有する1つまたは複数の刺激物質を含む刺激試薬、任意でオリゴマー刺激試薬を該固定相に加え、それによって、該刺激試薬、任意でオリゴマー刺激試薬と該複数のT細胞のうちの1つまたは複数とのインキュベーションを開始する工程;および
（c）インキュベーション開始から24時間以内に、該複数のT細胞のうちの1つまたは複数を重力流によって該固定相から収集し、それによって、刺激されたT細胞を含む組成物を生成する工程。 A method for on-column stimulation of T cells comprising the following steps:
(a) adding a sample comprising a plurality of T cells to a stationary phase contained in a chromatography column , wherein the stationary phase selects one or more of the plurality of T cells on the surface; comprising a selection agent that binds to a marker, whereby said one or more of a plurality of T cells are immobilized on said stationary phase;
(b) adding to said stationary phase a stimulating reagent comprising one or more stimulating substances , optionally oligomeric stimulating reagents, having the ability to deliver a stimulating signal in one or more of said plurality of T cells, thereby , initiating incubation of said stimulating reagent, optionally oligomeric stimulating reagent , with one or more of said plurality of T cells ; and (c) within 24 hours of initiating incubation, among said plurality of T cells from said stationary phase by gravity flow, thereby producing a composition comprising stimulated T cells.
（1）（a）複数のT細胞を含む試料と（b）該複数のT細胞のうちの1つまたは複数の表面に発現した選択マーカーに特異的に結合する能力を有する選択物質を含む固定相とを混合する工程であって、該固定相が、クロマトグラフィーカラムに含まれ、選択マーカーに対する該選択物質の特異的結合が、該複数のT細胞のうちの該1つまたは複数を該固定相に固定化する、工程;
（2）T細胞において刺激シグナルを送達する能力を有する1つまたは複数の刺激物質を含む刺激試薬、任意でオリゴマー刺激試薬を該固定相に加え、それによって、該刺激試薬、任意でオリゴマー刺激試薬と該1つまたは複数のT細胞とのインキュベーションを開始する工程;および
（3）インキュベーション開始から24時間以内に、該複数のT細胞のうちの1つまたは複数を重力流によって該固定相から収集し、それによって、刺激されたT細胞を含む組成物を生成する工程。 A method for on-column stimulation of T cells comprising the following steps:
(1) (a) a sample comprising a plurality of T cells and (b) an immobilization comprising a selection agent capable of specifically binding to one or more surface-expressed selectable markers of the plurality of T cells said stationary phase is contained in a chromatography column and said specific binding of said selection agent to a selectable marker immobilizes said one or more of said plurality of T cells; immobilizing in a phase, step;
(2) a stimulating reagent comprising one or more stimulating substances capable of delivering a stimulating signal in T cells , optionally an oligomeric stimulating reagent , is added to said stationary phase, thereby adding said stimulating reagent, optionally an oligomeric stimulating reagent; and (3) collecting one or more of said plurality of T cells from said stationary phase by gravity flow within 24 hours of initiating incubation with said one or more T cells; and thereby producing a composition comprising the stimulated T cells.
(a) オリゴマー刺激試薬を、固定相に固定化された複数のT細胞を含む固定相に加え、それによって、該刺激試薬と該複数のT細胞のうちの1つまたは複数のT細胞とのインキュベーションを開始する工程であって、
該固定相が、クロマトグラフィーカラムに含まれ、かつ1つまたは複数のT細胞の表面上の選択マーカーに特異的に結合する選択物質を含み、該1つまたは複数のT細胞によって発現された該選択マーカーへの該選択物質の特異的結合が、該1つまたは複数のT細胞を該固定相に固定化し、
該オリゴマー刺激試薬が、（i）複数のストレプトアビジン分子またはストレプトアビジンムテイン分子と（ii）1つまたは複数のT細胞において刺激シグナルを送達する能力を有する1つまたは複数の刺激物質とを含み、該オリゴマー刺激試薬のサイズが、（i）50nm超の半径、（ii）少なくとも5×106g/molの分子量および/または（iii）少なくとも100個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体を含む、
工程；ならびに
(b) インキュベーション開始から24時間以内に、複数のT細胞のうちの1つまたは複数を重力流によって固定相から収集し、それによって、刺激されたT細胞を含む組成物を生成する工程。 A method for on-column stimulation of T cells comprising the following steps:
(a) adding an oligomeric stimulating reagent to a stationary phase comprising a plurality of T cells immobilized on the stationary phase, thereby allowing the stimulating reagent to interact with one or more T cells of the plurality of T cells; initiating the incubation,
wherein said stationary phase is contained in a chromatography column and comprises a selection agent that specifically binds to a selectable marker on the surface of one or more T cells and expressed by said one or more T cells; specific binding of the selection agent to the selectable marker immobilizes the one or more T cells to the stationary phase;
said oligomeric stimulatory reagent comprises (i) a plurality of streptavidin molecules or streptavidin mutein molecules and (ii) one or more stimulatory agents capable of delivering a stimulatory signal in one or more T cells; The size of said oligomeric stimulating reagent is (i) a radius greater than 50 nm, (ii) a molecular weight of at least 5 x 106 g/mol and/or (iii) at least 100 streptavidin tetramers or streptavidin muteins. containing a tetramer,
process ;
(b) collecting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours of starting the incubation, thereby producing a composition comprising the stimulated T cells .
Trp-Arg-His-Pro-Gln-Phe-Gly-Gly (SEQ ID NO: 7)，Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 8)，Ser-Ala-Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 3 -Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO:15)，SAWSHPQFEKGGGSGGGSGGSAWSHPQFEK (SEQ ID NO:16)，Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 3 -Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 17)，Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 2 -Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 18)，および Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 2 Gly-Gly-Ser-Ala-Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 19)
からなる群より選択され、
ストレプトアビジンムテインが、SEQ ID NO:1に示すアミノ酸の配列におけるストレプトアビジン中の位置を基準として位置44～47に対応する配列位置に、アミノ酸配列Ile 44 -Gly 45 -Ala 46 -Arg 47 またはVal 44 -Thr 45 -Ala 46 -Arg 47 を含み、任意でストレプトアビジンムテインが、SEQ ID NO: 3～6、27～28、および104～105のいずれかに示すアミノ酸配列を含む、
請求項7または8記載の方法。 A streptavidin molecule or streptavidin mutein molecule reversibly binds to biotin, a biotin analog or a streptavidin-binding peptide, and optionally the streptavidin-binding peptide is
Trp-Arg-His-Pro-Gln-Phe-Gly-Gly (SEQ ID NO: 7), Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 8), Ser-Ala- Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 3 -Trp -Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 15), SAWSHPQFEKGGGSGGGSGGSAWSHPQFEK (SEQ ID NO: 16), Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 3 -Trp -Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 17), Trp-Ser -His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 2 -Trp -Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 18), and Trp-Ser-His-Pro- Gln-Phe-Glu-Lys-(GlyGlyGlySer) 2 Gly-Gly-Ser-Ala-Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 19)
selected from the group consisting of
The streptavidin mutein has the amino acid sequence Ile 44 -Gly 45 -Ala 46 -Arg 47 or Val at sequence positions corresponding to positions 44-47 relative to positions in streptavidin in the sequence of amino acids shown in SEQ ID NO:1. 44 -Thr 45 -Ala 46 -Arg 47 and optionally the streptavidin mutein comprises the amino acid sequence set forth in any of SEQ ID NOs: 3-6, 27-28, and 104-105;
9. A method according to claim 7 or 8 .
請求項2～13のいずれか一項記載の方法。 The one or more stimulatory and/or selective agents are independently antibodies, antibody fragments , proteinaceous binding molecules with immunoglobulin-like function, molecules containing Ig domains, cytokines, chemokines, aptamers, MHC molecules, a substance selected from the group consisting of MHC-peptide complexes , receptor ligands , and binding fragments of any of the foregoing ;
A method according to any one of claims 2-13 .
選択マーカーがT細胞抗原受容体複合体のメンバーであり;
選択マーカーがCD3鎖であり;
選択マーカーがCD3ゼータ鎖であり;
選択マーカーがCD8であり;
選択マーカーがCD4であり;
選択マーカーがCD45RAであり;
選択マーカーがCD27であり;
選択マーカーがCD28であり; および/または
選択マーカーがCCR7であり;
任意で選択マーカーが、CD3、CD4およびCD8からなる群より選択される、
請求項1～19のいずれか一項記載の方法。 the selectable marker is a T cell co-receptor;
the selectable marker is a member of the T cell antigen receptor complex ;
the selectable marker is the CD3 chain ;
the selectable marker is the CD3 zeta chain ;
the selectable marker is CD8 ;
the selectable marker is CD4 ;
the selectable marker is CD45RA ;
the selectable marker is CD27 ;
the selectable marker is CD28 ; and/or the selectable marker is CCR7 ;
optionally the selectable marker is selected from the group consisting of CD3, CD4 and CD8;
A method according to any one of claims 1-19 .
オリゴマー刺激試薬が、固形支持体に結合しておらず、かつ/または
オリゴマー刺激試薬が、フレキシブルであり、金属コアも磁気コアも含有せず、完全にもしくは主として有機多量体で構成され、かつ/もしくは剛直ではない、
請求項1および3～22のいずれか一項記載の方法。 the oligomer stimulating reagent is soluble,
the oligomeric stimulating reagent is not bound to a solid support and /or
the oligomeric stimulating reagent is flexible, contains no metallic or magnetic core, is composed entirely or primarily of organic polymers, and/or is not rigid;
The method of any one of claims 1 and 3-22.
両端の値を含む50nm～150nm、75nm～125nm、80nm～115nmもしくは90nm～110nmの半径、
5×10 7 g/mol～5×10 8 g/mol、1×10 8 g/mol～5×10 8 g/mol、もしくは1×10 8 g/mol～2×10 8 g/molの分子量、かつ／または
1,000～20,000個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体、1,000～10,000個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体、もしくは2,000～5,000個のストレプトアビジン四量体もしくはストレプトアビジンムテイン四量体
を含む、請求項1および3～23のいずれか一項記載の方法。 the oligomer stimulating reagent is
radii from 50 nm to 150 nm, 75 nm to 125 nm, 80 nm to 115 nm, or 90 nm to 110 nm, inclusive;
Molecular weight from 5×10 7 g/mol to 5×10 8 g/mol, from 1×10 8 g/mol to 5×10 8 g/mol, or from 1×10 8 g/mol to 2×10 8 g/mol , and/or
1,000-20,000 streptavidin tetramers or streptavidin mutein tetramers, 1,000-10,000 streptavidin tetramers or streptavidin mutein tetramers, or 2,000-5,000 streptavidin tetramers or streptavidin mutein tetramer
The method of any one of claims 1 and 3-23, comprising
重力流によって収集することが、T細胞を固定相から溶出させるための固定相への競合剤もしくは遊離結合剤の添加なしに実施され、任意で競合剤もしくは遊離結合剤が、固定相からの1つもしくは複数のT細胞の脱離を促進し、
重力流によって収集することが、固定相からT細胞を溶出させるための競合剤も遊離結合剤も含まない培地を固定相に加えることを含む、かつ／または
競合剤もしくは遊離結合剤が、ビオチンもしくはビオチン類似体、任意でD-ビオチンを含む、
請求項1～26のいずれか一項記載の方法。 incubating with one or more stimulating agents releases one or more of the plurality of immobilized T cells from the stationary phase; and/or
Harvesting by gravity flow is performed without the addition of competitors or free binders to the stationary phase to elute the T cells from the stationary phase, and optionally the competitors or free binders are separated from the stationary phase by promoting detachment of one or more T cells,
Collecting by gravity flow comprises adding medium to the stationary phase without competitors or free binders to elute the T cells from the stationary phase, and/or
the competitor or free binding agent comprises biotin or a biotin analogue, optionally D-biotin;
27. The method of any one of claims 1-26 .
競合剤もしくは遊離結合剤の添加が、該競合剤も該遊離結合剤も使用しない同等もしくは同じ条件下でのT細胞のインキュベーションとの比較で、生残するT細胞のパーセンテージを90％未満、80％未満、70％未満、60％未満もしくは50％未満に低減させることはない；かつ/または
前記解離が、T細胞における刺激シグナルを終結もしくは軽減させる、
請求項40記載の方法。 Competitor or free binding agent is not harmful to T cells;
addition of competitor or free binding agent reduces the percentage of T cells that survive compared to incubation of T cells under equivalent or identical conditions without said competitor or said free binding agent by less than 90%, 80 %, less than 70%, less than 60% or less than 50% ; and/or
said dissociation terminates or abates stimulatory signals in T cells;
41. The method of claim 40 .
請求項40または41記載の方法。 Competing reagents or free binders independently correspond to streptavidin binding molecules; biotin , optionally 1 mM D-biotin ; biotin analogs , optionally streptavidin, or positions 44-47 of wild-type streptavidin a biotin analogue that specifically binds to a streptavidin mutein having the amino acid sequence Val44 - Thr45 - Ala46 - Arg47 or Ile44 - Gly45 - Ala46 - Arg47 at the sequence position ; or a metal chelator, optionally comprising a molecule selected from the group consisting of EDTA or EGTA ;
42. A method according to claim 40 or 41 .
T細胞がCD3＋T細胞を含むか、CD4＋および/もしくはCD8＋T細胞を含む、
請求項1～43のいずれか一項記載の方法。 the T cells comprise antigen-specific T cells or populations thereof, helper T cells or populations thereof, cytotoxic T cells or populations thereof, memory T cells or populations thereof, or regulatory T cells or populations thereof ; and/or
the T cells comprise CD3+ T cells or comprise CD4+ and/or CD8+ T cells;
44. The method of any one of claims 1-43 .
操作されたT細胞を含む組成物からT細胞サブセットを選択する工程を含み、その後に請求項30～44のいずれか一項記載のインキュベーションが行われ、選択された該T細胞サブセットがウイルス組込みのための条件下でインキュベートされる；
操作されたT細胞を含む組成物からT細胞サブセットを選択する工程を含み、その後に請求項32～44のいずれか一項記載の培養工程が行われ、選択された該T細胞サブセットが、T細胞を拡大培養するための条件下で培養される；かつ/または
操作されたT細胞を含む組成物からT細胞サブセットを選択する工程を含み、その後に請求項34～44のいずれか一項記載の採取が行われ、選択された該T細胞サブセットが、操作されたT細胞のアウトプット集団を作製するために採取される、
任意で、選択する工程がアフィニティーカラムクロマトグラフィーによって実行される、
請求項1～44のいずれか一項記載の方法。 comprising the step of selecting a T cell subset from the stimulated T cells of said composition, followed by the introduction of any one of claims 28-44 , wherein the selected T cell subset comprises a recombinant nucleic acid a molecule is introduced ;
selecting a T cell subset from a composition comprising engineered T cells, followed by an incubation according to any one of claims 30 to 44, wherein said selected T cell subset is susceptible to viral integration. is incubated under conditions for;
comprising the step of selecting a T cell subset from a composition comprising engineered T cells, followed by the culturing step of any one of claims 32-44, wherein the selected T cell subset is a T cultured under conditions for cell expansion; and/or
comprising the step of selecting a T cell subset from a composition comprising engineered T cells, followed by collecting according to any one of claims 34-44, said selected T cell subsets being engineered collected to generate an output population of T cells,
optionally, the selecting step is performed by affinity column chromatography,
45. The method of any one of claims 1-44 .
固定相が非磁性材料もしくは非磁化可能材料である；
固定相が、固定相1mLあたりT細胞約7500万～約1億2500万個、任意で細胞20億±5億個の結合容量を有する；かつ/または
固定相が約20mLである、
請求項1～46のいずれか一項記載の方法。 the stationary phase comprises a chromatographic matrix ;
the stationary phase is a non-magnetic or non-magnetizable material;
the stationary phase has a binding capacity of about 75 million to about 125 million T cells, optionally 2 billion ± 500 million cells per mL of stationary phase; and/or
the stationary phase is about 20 mL,
47. The method of any one of claims 1-46 .
（b）固定相上にT細胞を固定化するための、T細胞上の選択マーカーに特異的に結合する能力を有する選択物質を含む、固定相と
を含む、T細胞のオンカラム刺激のための製造物品。 (a) a first stimulating agent and a second stimulating agent capable of specifically binding to a first molecule and a second molecule, respectively, on the surface of a T cell, for stimulating the T cell;
(b) for immobilizing T cells on a stationary phase, for on-column stimulation of T cells, comprising a stationary phase comprising a selective agent capable of specifically binding to a selectable marker on T cells; Manufactured goods.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862753911P | 2018-10-31 | 2018-10-31 | |
| US62/753,911 | 2018-10-31 | ||
| US201962842511P | 2019-05-02 | 2019-05-02 | |
| US62/842,511 | 2019-05-02 | ||
| US201962861314P | 2019-06-13 | 2019-06-13 | |
| US62/861,314 | 2019-06-13 | ||
| PCT/EP2019/079746 WO2020089343A1 (en) | 2018-10-31 | 2019-10-30 | Methods for selection and stimulation of cells and apparatus for same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512872A JP2022512872A (en) | 2022-02-07 |
| JPWO2020089343A5 true JPWO2020089343A5 (en) | 2022-11-07 |
Family
ID=68461775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523658A Pending JP2022512872A (en) | 2018-10-31 | 2019-10-30 | Methods for cell selection and stimulation and equipment for them |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220002669A1 (en) |
| EP (1) | EP3874024A1 (en) |
| JP (1) | JP2022512872A (en) |
| KR (1) | KR20210098450A (en) |
| CN (1) | CN113227358A (en) |
| AU (1) | AU2019370705A1 (en) |
| BR (1) | BR112021008133A2 (en) |
| CA (1) | CA3117568A1 (en) |
| IL (1) | IL282757A (en) |
| MX (1) | MX2021005013A (en) |
| SG (1) | SG11202104355SA (en) |
| WO (1) | WO2020089343A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY184699A (en) | 2014-04-16 | 2021-04-18 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
| MA45489A (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | CELL CULTURE PROCESSES, ASSOCIATED KITS AND APPARATUS |
| MA45426A (en) | 2015-10-22 | 2019-05-01 | Juno Therapeutics Gmbh | TRANSDUCTION PROCESSES, KITS, AGENTS AND APPARATUS |
| MA45488A (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | CELL CULTURE PROCESSES, KITS AND APPARATUS |
| NZ758485A (en) | 2017-04-27 | 2024-02-23 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| KR20220131892A (en) | 2019-11-05 | 2022-09-29 | 주노 쎄러퓨티크스 인코퍼레이티드 | Methods for determining the properties of therapeutic T-cell compositions |
| EP4178590A1 (en) * | 2020-07-09 | 2023-05-17 | The Board of Trustees of the Leland Stanford Junior University | Multi-parallel analysis of t-cell therapies |
| CN117916256A (en) * | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | Methods for stimulating and transducing T cells |
| WO2023080178A1 (en) * | 2021-11-02 | 2023-05-11 | Ａｇｃ株式会社 | Method for producing car-t cells |
| WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| CN115625624B (en) * | 2022-12-21 | 2023-03-17 | 太原理工大学 | Device for cleaning complex cavity of casting casing |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| EP0198015B2 (en) | 1984-10-02 | 1995-07-19 | Biogen, Inc. | Production of streptavidin-like polypeptides |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| IN165717B (en) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| WO1992008796A1 (en) | 1990-11-13 | 1992-05-29 | Immunex Corporation | Bifunctional selectable fusion genes |
| DE4228458A1 (en) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronic expression units and their use |
| DE4237113B4 (en) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptides and their fusion proteins, expression vector and method of producing a fusion protein |
| WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| JPH08511166A (en) | 1993-06-04 | 1996-11-26 | アメリカ合衆国 | Method for selectively stimulating T cell proliferation |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| JPH11501008A (en) | 1995-02-09 | 1999-01-26 | ユニバーシティ オブ ワシントン | Modified-affinity streptavidin |
| US6022951A (en) | 1995-04-11 | 2000-02-08 | Univ Boston | Streptavidin mutants |
| US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
| DE19608753C1 (en) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduction system based on rep-negative adeno-associated virus vector |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| ATE186235T1 (en) | 1996-04-24 | 1999-11-15 | Claude Fell | CELL SEPARATION DEVICE FOR BIOLOGICAL LIQUIDS SUCH AS BLOOD |
| DE19641876B4 (en) | 1996-10-10 | 2011-09-29 | Iba Gmbh | streptavidin muteins |
| CA2283716A1 (en) | 1997-03-14 | 1998-09-17 | Gabriel O. Reznik | Multiflavor streptavidin |
| EP1019439B1 (en) | 1997-10-02 | 2011-11-16 | Altor BioScience Corporation | Soluble single-chain t-cell receptor proteins |
| US5985658A (en) | 1997-11-14 | 1999-11-16 | Health Research Incorporated | Calmodulin-based cell separation technique |
| EP1066380B1 (en) | 1998-05-19 | 2001-11-14 | Avidex Ltd | Soluble t cell receptor |
| DK1616579T3 (en) | 1998-05-23 | 2009-09-14 | Univ Leiden Medical Ct | CD40 binding molecules and CTL peptides for the treatment of tumors |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US6733433B1 (en) | 1998-12-24 | 2004-05-11 | Biosafe S.A. | Blood separation system particularly for concentrating hematopoietic stem cells |
| DE19932688B4 (en) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design of beta-sheet proteins of gamma-II-crystalline antibody-like |
| JP2003524644A (en) | 2000-02-01 | 2003-08-19 | タノックス インコーポレイテッド | CD40-binding APC-activating molecule |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| CA2410510A1 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| ATE338124T1 (en) | 2000-11-07 | 2006-09-15 | Hope City | CD19-SPECIFIC TARGETED IMMUNE CELLS |
| EP1227321A1 (en) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
| DE10113776B4 (en) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isolated streptavidin-binding, competitively elutable peptide, this comprehensive fusion peptide, nucleic acid coding therefor, expression vector, methods for producing a recombinant fusion protein and methods for detecting and / or obtaining the fusion protein |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| MXPA04001974A (en) | 2001-08-31 | 2004-07-16 | Avidex Ltd | Soluble t cell receptor. |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2007001459A2 (en) | 2004-11-15 | 2007-01-04 | Washington University | Compositions and methods for modulating lymphocyte activity |
| FR2841905B1 (en) | 2002-07-05 | 2004-09-03 | Centre Nat Rech Scient | FAB MUTANTS OF CHIMERE 13B8.2 ANTI-CD4 ANTIBODIES AND THEIR APPLICATIONS |
| CA2501870C (en) | 2002-10-09 | 2013-07-02 | Avidex Limited | Single chain recombinant t cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| DE602004005338T2 (en) | 2003-05-16 | 2007-12-13 | Université Libre de Bruxelles | DIGITAL HOLOGRAPHIC MICROSCOPE FOR THREE-DIMENSIONAL ILLUSTRATION AND METHOD OF USE THEREOF |
| US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20060034850A1 (en) | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| ATE475669T1 (en) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | CELLS EXPRESSING A MODIFIED T-CELL RECEPTOR |
| CA2586615C (en) | 2004-11-12 | 2017-06-27 | Genentech, Inc. | Pro87299 (btla), and variants thereof, for treating immune related disorders |
| EP1893253B1 (en) | 2005-03-23 | 2010-05-19 | Biosafe S.A. | Integrated system for collecting, processing and transplanting cell subsets, including adult stem cells, for regenerative medicine |
| GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| NO2856876T3 (en) | 2007-03-30 | 2018-06-30 | ||
| AU2008247382B2 (en) | 2007-05-07 | 2014-06-05 | Medimmune, Llc | Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| JP5173594B2 (en) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | Management apparatus, image forming apparatus, and processing method thereof |
| CA3138111A1 (en) | 2008-08-26 | 2010-03-04 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| NZ594985A (en) | 2009-03-10 | 2013-07-26 | Biogen Idec Inc | Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies |
| CA2777053A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| AU2010315243B2 (en) | 2009-11-03 | 2016-08-25 | City Of Hope | Truncated epidermal growth factor receptor (EGFRt) for transduced T cell selection |
| PL3214091T3 (en) | 2010-12-09 | 2019-03-29 | The Trustees Of The University Of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| AU2011343887B2 (en) | 2010-12-14 | 2016-06-16 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer |
| NZ743310A (en) | 2011-03-23 | 2022-11-25 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| ES2785081T3 (en) | 2011-04-01 | 2020-10-05 | Memorial Sloan Kettering Cancer Center | Bispecific T-cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| EP3418295B1 (en) | 2011-07-18 | 2020-09-02 | IBA GmbH | Method of reversibly staining a target cell |
| CN108107197B (en) | 2011-07-19 | 2020-05-08 | 奥维茨奥成像系统公司 | Methods and systems for detecting and/or classifying cancer cells in a cell sample |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| BR112014011417B1 (en) | 2011-11-11 | 2021-10-13 | Fred Hutchinson Cancer Research Center | ISOLATED POLYPEPTIDE CAPABLE OF ELIGITING AN ANTIGEN-SPECIFIC T-CELL RESPONSE TO HUMAN CYCLIN A1 IMMUNOGENIC COMPOSITION INCLUDING SUCH POLYPEPTIDE, AS WELL AS A METHOD TO PREPARE CELLS PRESENTING SUPER ANTIGEN, ANTIGEN, ANTIGEN-USED ANTIGEN-USED CELLS |
| AU2013221672B2 (en) | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| JP6362543B2 (en) | 2012-02-23 | 2018-07-25 | ジュノ セラピューティクス ゲーエムベーハー | Chromatographic isolation of cells and other complex biological materials |
| JP6251734B2 (en) | 2012-05-03 | 2017-12-27 | フレッド ハッチンソン キャンサー リサーチ センター | Affinity enhanced T cell receptor and method for producing the same |
| PT2884999T (en) | 2012-08-20 | 2021-01-05 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| US9904248B2 (en) | 2012-09-20 | 2018-02-27 | Ovizio Imaging Systems NV/SA | Digital holographic microscope with fluid systems |
| WO2014055668A1 (en) | 2012-10-02 | 2014-04-10 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| EP2920204B1 (en) | 2012-11-16 | 2019-09-18 | IBA GmbH | Streptavidin muteins and methods of using them |
| TWI654206B (en) | 2013-03-16 | 2019-03-21 | 諾華公司 | Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor |
| MY184699A (en) | 2014-04-16 | 2021-04-18 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
| IL292038A (en) | 2014-04-23 | 2022-06-01 | Juno Therapeutics Inc | Methods for enriching or producing immune cell populations for adoptive therapy |
| WO2015168613A2 (en) | 2014-05-02 | 2015-11-05 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| TWI751102B (en) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | Antibodies and chimeric antigen receptors specific for cd19 |
| ES2688035T3 (en) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Universal antigen receptor that expresses immune cells for addressing multiple multiple antigens, procedure for manufacturing it and using it for the treatment of cancer, infections and autoimmune diseases |
| HUE050264T2 (en) | 2014-11-05 | 2020-11-30 | Juno Therapeutics Inc | Methods for transduction and cell processing |
| PT3226897T (en) | 2014-12-05 | 2021-04-13 | Eureka Therapeutics Inc | Antibodies targeting b-cell maturation antigen and methods of use |
| IL285101B2 (en) | 2014-12-05 | 2024-03-01 | Memorial Sloan Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
| CN113683711A (en) | 2014-12-05 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | Chimeric antigen receptor targeting G-protein coupled receptor and uses thereof |
| PL3227432T3 (en) | 2014-12-05 | 2024-03-11 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| WO2016166568A1 (en) * | 2015-04-16 | 2016-10-20 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
| MA45488A (en) * | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | CELL CULTURE PROCESSES, KITS AND APPARATUS |
| MA45489A (en) * | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | CELL CULTURE PROCESSES, ASSOCIATED KITS AND APPARATUS |
| IL303785A (en) | 2016-04-01 | 2023-08-01 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
| US11932870B2 (en) | 2016-12-05 | 2024-03-19 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP3595440A2 (en) | 2017-03-14 | 2020-01-22 | Juno Therapeutics, Inc. | Methods for cryogenic storage |
| NZ758485A (en) | 2017-04-27 | 2024-02-23 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| JP2020528885A (en) | 2017-07-19 | 2020-10-01 | フェイト セラピューティクス，インコーポレイテッド | Compositions and Methods for Immune Cell Regulation in Adoptive Immunotherapy |
-
2019
- 2019-10-30 SG SG11202104355SA patent/SG11202104355SA/en unknown
- 2019-10-30 EP EP19798040.2A patent/EP3874024A1/en active Pending
- 2019-10-30 WO PCT/EP2019/079746 patent/WO2020089343A1/en unknown
- 2019-10-30 CA CA3117568A patent/CA3117568A1/en active Pending
- 2019-10-30 CN CN201980086177.9A patent/CN113227358A/en active Pending
- 2019-10-30 BR BR112021008133-0A patent/BR112021008133A2/en unknown
- 2019-10-30 JP JP2021523658A patent/JP2022512872A/en active Pending
- 2019-10-30 US US17/289,690 patent/US20220002669A1/en active Pending
- 2019-10-30 AU AU2019370705A patent/AU2019370705A1/en active Pending
- 2019-10-30 MX MX2021005013A patent/MX2021005013A/en unknown
- 2019-10-30 KR KR1020217015787A patent/KR20210098450A/en unknown
-
2021
- 2021-04-28 IL IL282757A patent/IL282757A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230295567A1 (en) | Methods for culturing cells and kits and apparatus for same | |
| US20240101613A1 (en) | Oligomeric particle reagents and methods of use thereof | |
| US11913024B2 (en) | Methods for culturing cells and kits and apparatus for same | |
| US20210115401A1 (en) | Methods and Materials for the Generation of Regulatory T Cells | |
| RU2763795C2 (en) | Methods of isolating, culturing and genetic engineering cell populations of the immune system for adoptive therapy | |
| EP3877054B1 (en) | Process for producing genetically engineered t cells | |
| KR20210057730A (en) | Engineered cells and methods of producing compositions | |
| CA3117568A1 (en) | Methods for selection and stimulation of cells and apparatus for same | |
| JPWO2020089343A5 (en) | ||
| WO2016166568A1 (en) | Methods, kits and apparatus for expanding a population of cells | |
| CA3159380A1 (en) | Cell selection and/or stimulation devices and methods of use | |
| JP2024517863A (en) | Methods for stimulating and transducing cells | |
| RU2777989C2 (en) | Oligomeric reagents in form of particles and their application methods | |
| RU2778411C2 (en) | Methods for cultivation of cells and sets and device for them |